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ABSTRACT
Schizophrenia is a devastating psychiatric illness afflicting approximately 1% of the
world’s population. Currently, the disease mechanism is poorly understood and the
pharmacological interventions relieve only some of the symptoms. Schizophrenia
is highly heritable and genetic factors contribute to about 65-80% of the liability to
the illness. However, the genetic etiology is complex and remains largely unknown.
Potassium channels are key determinants of neuronal excitability. Kv2.1 is a
widely-expressed voltage-gated potassium channel α-subunit. Kv2.1 channels
constitute an essential component of the somatodendritic delayed rectifier current
(IK) in several neuronal types and regulate excitability, especially during periods of
high-frequency firing.
This study outlines the identification and characterization of a novel
neuronal transmembrane protein AMIGO, which contains extracellular
immunoglobulin (Ig) and leucine-rich repeat (LRR) domains. AMIGO was shown
to be widely expressed in cerebral neurons and localized to distinctive clusters in
the neuronal plasma membrane, restricted to the cell soma and proximal part of
neurites.  AMIGO  was  further  identified  as  an  auxiliary  subunit  of  the  Kv2.1
potassium channel. AMIGO and Kv2.1 were shown to display extensive spatial
and temporal colocalization and association in brain. AMIGO was also shown to
modify the voltage-dependent activation of Kv2.1 and neuronal delayed rectifier
current (IK).
To further understand the physiological role of AMIGO in brain, a mouse
line lacking the Amigo gene was created and characterized as part of this study.
Absence of AMIGO clearly reduced the amount of the Kv2.1 channel protein in
mouse brain and altered the voltage-dependent activation of neuronal IK. These
changes were accompanied by behavioral and pharmacological abnormalities
reminiscent of those identified in schizophrenia. Concomitantly, the rare KV2.1
variant was found to be associated with human schizophrenia. These findings
demonstrate the involvement of the AMIGO-Kv2.1 channel complex in
schizophrenia-related behavioral domains in mice and establish KV2.1 as  a
susceptibility gene for schizophrenia spectrum disorders in humans.
In the current study, AMIGO was identified as an integral component of the
Kv2.1 channel complex in brain. The convergent findings in humans and mice
suggest a role for the AMIGO-Kv2.1 potassium channel complex in the
pathophysiology of schizophrenia. Furthermore, these findings suggest AMIGO
and Kv2.1 may represent potential new targets for schizophrenia treatment
development.
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1. INTRODUCTION
1.1 Overview
A novel neuronal transmembrane protein, AMIGO, was identified in the early
stages of this project (Publication I). AMIGO belongs to the group of LRR
proteins, and the extracellular part of AMIGO contains LRR and Ig domains.
Both of these domains are important in protein-ligand interactions. Many of the
genes encoding extracellular LRRs are expressed in the nervous system (Chen et al,
2006; de Wit et al, 2011). Some of the LRR proteins are involved in cellular
processes such as axon guidance, target selection, synapse formation, myelination
and growth inhibition (de Wit et al, 2011). Several LRR proteins are implicated in
neurological and psychiatric disorders (Aoki-Suzuki et al, 2005; Francks et al, 2007;
Kalachikov et al, 2002). However, the binding partners and functions of many of
extracellular LRR proteins remain unknown.
The main goal of this study was to examine the properties and the biological
function of AMIGO in the nervous system. The distribution of AMIGO was
characterized in detail with several methods. Unexpectedly, AMIGO was found to
display striking colocalization and association with voltage-dependent potassium
channel Kv2.1 (Publication II). Voltage-dependent potassium channels are
important regulators of neuronal excitability and signal transduction. Kv2.1
channels constitute an essential component of the somatodendritic delayed
rectifier current (IK)  in  several  neuronal  types  (Baranauskas  et  al,  1999;  Du et  al,
2000; Guan et al, 2007; Malin & Nerbonne, 2002; Mohapatra et al, 2009;
Murakoshi & Trimmer, 1999). We demonstrated that AMIGO modifies the
voltage-dependent activation of Kv2.1 and neuronal IK.
To further understand the physiological role of AMIGO in mouse brain, we
created a mouse line lacking Amigo gene  (Publication  III).  Absence  of  AMIGO
clearly reduced the amount of the Kv2.1 channel protein in mouse brain and
altered the voltage-dependent activation of neuronal IK. Unexpectedly, AMIGO
KO mice displayed several characteristics associated with schizophrenia. Our
results in mice clearly identified AMIGO1 and KV2.1 (KCNB1) as candidate genes
for human schizophrenia. Consequently, we detected an association of rare KV2.1
variant with human schizophrenia and schizophrenia spectrum disorders
(Publication III).
This study brings together LRR protein AMIGO, voltage-gated potassium
channel Kv2.1 and schizophrenia. An introduction to these subjects is provided in
the following chapters.
Introduction
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1.2 Leucine-rich repeat proteins
1.2.1 Characteristics of leucine-rich repeat proteins
Leucine-rich repeats (LRRs) are sequence motifs found in a large number of
proteins with diverse structures, locations, and functions in bacteria, fungi, plants,
and animals. The primary function of these motifs appears to be to provide a
versatile structural framework for the formation of protein-ligand interactions
(Kobe & Kajava, 2001).
LRRs are generally 20-29 amino acids in length and are unusually rich in the
hydrophobic amino-acid leucine. Each repeat contains an N-terminal conserved
part and a C-terminal variable part. The conserved part is defined by a consensus
sequence LxxLxLxxNxL or LxxLxLxxCxxL, where: x can be any amino acid; L is
hydrophobic amino acid leucine, valine, isoleucine, or phenylalanine; N is
asparagine, threonine, cysteine, or serine; and C is cysteine or serine (Kajava, 1998;
Kobe & Kajava, 2001). Structurally, this conserved part of the motif forms a β-
strand and a loop region. The C-terminal part of the repeat is more variable in
length, sequence and structure. (Enkhbayar et al, 2004; Kajava, 1998; Kobe &
Deisenhofer, 1994; Kobe & Kajava, 2001)
LRRs  exist  in  tandem arrays  of  several  repeats  (varying  from 2  to  52)  that
together constitute the LRR domain (Matsushima et al, 2005). The arrangement of
repeating sequence motifs generates a curved structure with the β-strands stacking
to form a β-sheet on the concave surface.  This is  the defining feature of all  LRR
domains. The variable parts of repeats form the convex surface of the curved
structure. Most LRR domains also have both N-terminal and C-terminal cap
regions, which shield the hydrophobic core of the LRR structure (Kobe & Kajava,
2001). In extracellular LRR proteins the capping regions are cysteine-rich motifs
with  a  conserved  set  of  disulfides.  The  structure  of  the  LRR  domain  in  several
LRR proteins is presented in Figure 1.
Many LRR proteins bind ligands with their concave surfaces (Kajander et al,
2011; Kobe & Deisenhofer, 1995; Morlot et al, 2007; Seiradake et al, 2009;
Seiradake et al, 2011). The curved structure of the LRR domain and the exposed β-
sheet on the concave side form a large binding surface, which makes the LRR
domains very effective protein-binding motifs (Kobe & Deisenhofer, 1994; Kobe
& Kajava, 2001). Variation in the length and number of repeats, and in secondary
structures on the convex side, creates variability in the curvature of the LRR
domain in different proteins allowing interactions with a large diversity of ligands.
1.2.2 Proteins with extracellular leucine-rich repeats
There are about 140 human genes encoding proteins with extracellular LRRs
(eLRRs) (Dolan et al, 2007). These include secreted, lipid-anchored, and various
types of transmembrane proteins. Many of the genes encoding extracellular LRRs
are expressed in the nervous system (Chen et al, 2006; de Wit et al, 2011). Because
Introduction
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the LRR domain is an efficient structure for protein-ligand interactions, proteins
with extracellular LRR domains are well suited to regulate intercellular
communication and cell adhesion. Interestingly, a comparative analysis of eLRR
genes has revealed that the eLRR superfamily has greatly expanded in mammals
and  to  a  lesser  extent  in  flies.  There  are  29  eLRR  proteins  in  worms,  66  eLRR
proteins in flies, and 135 eLRR proteins in mice (Dolan et al, 2007). The
evolutionary need for more molecules involved in adhesion and cell-cell
communication arises with the increasing complexity of the organism. In
particular, expansion of the eLRR protein superfamily is correlated with
complexity of the nervous system (Dolan et al, 2007).
Extracellular LRRs containing proteins have been divided into four
subgroups depending on their domain organization (Dolan et al, 2007). The LRR-
only class proteins do not contain other recognizable protein domains except
Figure 1. Structure of the
leucine-rich repeat (LRR)
domain. The ribbon diagram
of the LRR domain structure
from several proteins. (a)
Individual LRR from
ribonuclease inhibitor. The ɴ-
strand of the consecutive
LRR is also shown. (b) The
porcine ribonuclease
inhibitor (Kobe  &
Deisenhofer, 1993). (c)
Homology model of the
ectodomain of Drosophila
Capricious. (Choe et al,
2005). (d) Homology model
of the ectodomain of human
LRRTM2. (Mosyak et al,
2006). (e) Three-dimensional
structure of the second LRR
domain of Slit in complex
with the first Ig domain of
Robo1 (Morlot et al, 2007).
(f) Three-dimensional
structure of the LINGO-1
ectodomain.  Color  code:  ɴ-
strand (orange), loop region
(teal),  ɲ-helix  (red). Figure
courtesy of Davide
Comoletti, University of
California, San Diego.
Reprinted  from  de  Wit  et  al,
2011. Copyright © 2011,
Annual Reviews.
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LRRs. The LRR-Ig/FN3 class proteins contain LRRs and immunoglobulin (Ig)
and/or fibronectin type 3 (FN3) domains. The LRR-Tollkin class proteins contain
LRRs and a cytoplasmic Toll/interleukin 1 receptor domain or cluster with Toll
proteins. The LRR-other class consists of proteins that contain LRRs and some
other  types  of  domains,  e.g.  epidermal  growth  factor  (EGF)  repeats  or  a  G-
protein-coupled receptor domain.
The binding partners and functions of many of eLRR proteins are still
unknown. Among eLRR proteins with known binding partners, a large structural
variability exists in ligand structure. Well-known LRR proteins in the nervous
system include Trk neurotrophin receptors, Nogo receptor (NgR) mediating
axonal growth inhibition, and Slit family of extracellular axon-guiding proteins (de
Wit et al, 2011; Schwab, 2010). Many eLRR proteins have functions in the innate
immune system that are similar in plants and animals (Nürnberger et al, 2004).
Many others are involved in various aspects of nervous system development and
function  (Chen  et  al,  2006;  de  Wit  et  al,  2011).  In  the  nervous  system,  LRR
proteins are involved in cellular processes such as axon guidance, target selection,
synapse formation, myelination, and growth inhibition. Several LRR proteins are
implicated in neurological and psychiatric disorders, including Alzheimer’s disease,
Tourette’s syndrome, night blindness, epilepsy, autism, bipolar disorder, and
schizophrenia (Abelson et al, 2005; Aoki-Suzuki et al, 2005; Bech-Hansen et al,
2000; de Wit & Ghosh, 2014; Francks et al, 2007; Kalachikov et al, 2002). Figure 2
represents selected neural eLRR proteins grouped by their associated functions.
1.2.3 LRRIG proteins
Immunoglobulin (Ig) domains are important in protein interactions. An Ig domain
is found in many proteins with different functions, including antibodies, cell
adhesion molecules, and cell receptors (Williams & Barclay, 1988). These proteins
can bind other Ig domain containing proteins or a variety of other molecules, such
as antigens and sugars. In cell adhesion molecules, the Ig domain can mediate both
homophilic and heterophilic molecular interactions. Structurally, the Ig domain is a
sandwich like structure with two antiparallel β-sheets joined together by a
conserved cysteine bridge (Bork et al, 1994).
Proteins  that  simultaneously  carry  both  LRR  and  Ig  domains  are  called
LRRIG proteins/LIG proteins (Homma et al, 2009; MacLaren et al, 2004; Mandai
et al, 2009). The domain structure of these proteins combines two versatile
binding domains and thus enhances the potential for a wide spectrum of protein-
protein interactions.
At least 36 human LRRIG proteins have been identified comprising 13
subgroups: four LINGO proteins, three NGL proteins, five SALM proteins, three
NLRR proteins, three Pal proteins, two ISLR proteins, three LRIG, two GPR, two
Adlican, two Peroxidasin-like proteins, three Trk receptors, an unnamed protein
Introduction
5
Figure 2. Domain organization and function of selected neural LRR proteins. The schematic
overview shows the domain organization of selected extracellular LRR proteins with known
functions in the nervous system. The proteins are grouped by the cellular processes that they
regulate. Protein names are indicated below the diagrams, in red for fly LRR proteins and in
blue for mammalian LRR proteins. Domain abbreviations: CT3, cysteine-knot; EGF, epidermal
growth factor-like; EPTP, epitempin; FN3, fibronectin type III; GPI,
glycosylphosphatidylinositol; Ig, immunoglobulin-like; laminin G, laminin globular; LRRNT and
LRRCT,  LRR  N-  and  C-terminal  flanking  domains;  PDZ-IS,  PDZ  interaction  site;  TIR,
Toll/interleukin-1 receptor; TyrK, tyrosine kinase. Reprinted from de Wit et al, 2011.
Copyright © 2011, Annual Reviews.
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AA11068 and three AMIGO proteins (Homma et al, 2009). Adlican and
Peroxidasin are secreted proteins whereas the remaining 11 of these subgroups are
membrane associated proteins. Interestingly, most of these proteins -if not all- are
expressed in the nervous system (Homma et al, 2009; Kuhnert et al, 2010;
Nagasawa  et  al,  1999).  Some  are  nervous  system  specific,  whereas  some  are
expressed more broadly. Many of these proteins have been associated with
neuronal growth modulating functions (Chen et al, 2006).
1.3 AMIGO protein family
1.3.1 Identification of AMIGO protein family
At  the  early  stages  of  this  project,  a  novel  family  of  three  homologous  cell
adhesion molecules was identified (Publication I). AMIGO (amphoterin-induced
gene  and  ORF)  was  identified  as  a  gene  induced  by  the  neurite  outgrowth-
promoting protein HMGB1 (amphoterin) in cultured hippocampal neurons. Two
other genes were cloned on the basis of their homology to AMIGO. These
molecules were named AMIGO2 and AMIGO3. AMIGO proteins contain both
immunoglobulin (Ig) and leucine-rich repeat (LRR) domains and thus belong to
the group of LRRIG proteins. The domain structure of AMIGO is presented in
Figure 8. The identification, characterization and functional studies of AMIGO are
described in detail in the Results section of this thesis. The subsequent
introductory chapters include the information about AMIGO protein family
published following their identification, by our group or by others, which is not
included in the Results section of this thesis.
1.3.2 Expression of AMIGO
The distribution of AMIGO mRNA in embryonic and adult mouse tissues was
first described by Kuja-Panula et al, 2003 (Publication I). The expression of
AMIGO mRNA during development has been studied with in situ hybridization in
early  (E10)  mouse  embryos  (Homma et  al,  2009).  In  the  central  nervous  system,
AMIGO expression was detected in post-mitotic neurons in the developing
forebrain, midbrain and hindbrain. In the peripheral nervous system, AMIGO was
expressed  in  all  cranial  and  dorsal  root  ganglia.  Outside  the  nervous  system,
AMIGO mRNA was expressed in the inner mesenchyme cells in the branchial
arches and limb bud. Mandai et al. (2009) have also detected AMIGO mRNA
expression in mouse embryonic (E13.5) dorsal root ganglion neurons.
AMIGO-like immunoreactivity was initially located in central nervous
system  axonal  tracts  (Publication  I).  It  has  also  been  reported  that  AMIGO-like
immunostaining is present in multiple brain cell types in adult mouse brain,
including neurons, astrocytes, and oligodendrocytes (Chen et al, 2012). According
to Chen et al, neuronal AMIGO-like immunosreactivity was mostly restricted to
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cell body and dendrites. However, the specificity of AMIGO antibody used in
these studies has not been characterized with AMIGO knockout tissue. Cellular
and subcellular distribution of specific (knockout tissue-validated) AMIGO
immunoreactivity in adult mouse brain is described in the Results (Publication II).
1.3.3 Structure of AMIGO
The crystal structure of the AMIGO ectodomain has been determined (Figure 3)
(Kajander et al, 2011). The LRR domain of AMIGO forms a typical curved LRR
structure with the β-sheet on the concave surface. The LRR domain contains
cysteine-rich N- and C-terminal capping regions with two disulfide bridges in each.
The LRR domain is followed by the C-terminal, membrane-proximal C2-type Ig-
domain.  The crystal  structure reveals  AMIGO as a dimeric protein with the LRR
regions forming the dimeric interface. It is suggested that all three AMIGO
proteins  form  similar  dimers,  as  some  key  aromatic  residue  interactions  at  the
dimer interface are conserved in all AMIGO proteins, while the convex surface is
not conserved (Kajander et al, 2011). Mutagenesis studies indicate that
dimerization is necessary for the proper cell-surface expression of AMIGO
(Kajander et al, 2011).
Figure 3. Structure of AMIGO.
Ribbon diagram of AMIGO
monomer  (a)  and  dimer  (c).  ɴ-
strands in pale cyan, helices in red
and the Ig domain in blue. The
glycan  at  Asn72 as  is  shown in  stick
(gray). (b) Domain structure: the
LRRs  in  monomer  fold  are  colored
cyan, C-terminal capping motif is in
red, N-terminal capping motif is in
blue, and Ig domain is shown in gray
(behind the red LRRCT). Reprinted
from Kajander et al, 2011, Copyright
©2011, with permission from
Elsevier.
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1.3.4 Functional role of AMIGO
In vitro studies  have  suggested  that  AMIGO  acts  as  a  homophilic  adhesion
molecule that induces outgrowth and fasciculation of neurites in central neurons
(Publication I). In zebrafish, AMIGO affects the development of neural circuits,
and its mechanism is suggested to involve homophilic interactions within the
developing fiber tracts (Zhao et al, 2014). Clear defects in corresponding neuronal
circuits are not seen in adult AMIGO knockout mice (the Results section,
Publication III). However, these circuits have not been studied during
development in AMIGO knockout mouse.
AMIGO has also been suggested to regulate dendritic growth and neuronal
survival (Chen et al, 2012). Suppression of AMIGO expression with siRNA
reduced the number and length of dendrites in cultured cortical neurons (Chen et
al, 2012). In a heterologous expression system, SH-SY5Y cells stably expressing
AMIGO were more resistant to experimentally induced apoptosis (Chen et al,
2012).
 
1.3.5 Expression of AMIGO2
The expression of AMIGO2 mRNA during development has been studied with in
situ hybridization in early (E10) mouse embryos (Homma et al, 2009). AMIGO2
mRNA expression was found primarily in the central nervous system and it was
observed only in a small number of post-mitotic cells in the developing forebrain
and midbrain. Outside the nervous system, AMIGO2 expression was observed
only in the mesonephros.
The expression of AMIGO2 mRNA in adult mouse brain has been studied
in detail with in situ hybridization (Laeremans et al, 2013). The expression of
AMIGO2 was detected in restricted brain areas, including the mitral cell layer of
the olfactory bulb, the granular cell layer of the accessory olfactory bulb, preoptic
area, habenula, premammillary nuclei, hippocampus, and cerebellum. The
expression pattern of AMIGO2 was especially distinct in the hippocampus.
AMIGO2 was restricted to specific subfields of the hippocampus including CA2
and CA3a, and the expression was absent from other hippocampal areas. Similar
highly restricted expression in the hippocampus has been detected with reporter
gene analysis in heterozygous AMIGO2 knockout mice (unpublished
observations, Kathleen Gransalke). In addition to the nervous system, AMIGO2
mRNA expression has been detected in adult mouse spleen, lung, kidney, small
intestine, and testis with RT-PCR (Kuja-Panula et al, 2003).
The expression of AMIGO2/DEGA has been studied in selected tumor
and  normal  human  tissues  outside  the  nervous  system  (Rabenau  et  al,  2004).  In
normal tissues, the strongest expression of AMIGO2 was observed in breast,
ovary, uterus, and cervix. Lower expression levels were detected in lung, colon,
and rectum.
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1.3.6. Functional role of AMIGO2
Following identification of three AMIGOs (Kuja-Panula et al, 2003), AMIGO2
has been identified in two separate studies (Ono et al, 2003; Rabenau et al, 2004).
In these studies AMIGO2 was called as Alivin 1 (after “alive” and “activity-
dependent leucine-rich repeat and Ig superfamily survival-related protein”) or
DEGA (differentially expressed in human gastric adenocarcinomas).
Alivin1 was identified as a gene whose expression is tightly associated with
depolarization and/or NMDA-dependent survival of cerebellar granule neurons
(Ono  et  al,  2003).  The  study  also  demonstrated  that  the  expression  of
AMIGO2/Alivin 1 is dependent on neuronal activity. Furthermore, it was shown
that AMIGO2/Alivin 1 promoted depolarization-dependent survival of cerebellar
granule neurons in cultures.
DEGA was identified as a gene differentially expressed in human gastric
adenocarcinomas (Rabenau et al, 2004). The expression of AMIGO2/DEGA was
increased in tumor versus normal tissue in approximately 45% of gastric
adenocarcinoma patient samples. Differential expression of AMIGO2 was also
detected in thyroid and pancreatic tumors (Rabenau et al, 2004). Suppression of
AMIGO2 expression with iRNA in a gastric adenocarcinoma cell line abrogated
their tumorigenicity in nude mice, and led to altered adhesion/migration as well as
cytogenetic and morphological cell properties (Rabenau et al, 2004).
1.4 Voltage-gated potassium channels
1.4.1 Characteristics of voltage-gated potassium channels
Potassium (K+) channels are membrane proteins that form a potassium-selective
pore across the membrane. K+ channels regulate the membrane potential and
excitability of neurons and other cell types. They are essential for a wide variety of
fundamental physiological processes, including endocrine secretion, T-cell
proliferation, muscle contraction, cardiac-rhythm generation, and neuronal signal
transduction. Accordingly, potassium channels are important targets of drug
development. There are four major classes of K+ channels: voltage-gated K+
channels (Kv), Ca2+ activated  K+ channels (KCa), inwardly rectifying K+ channels
(Kir),  and two-pore-domain K+ channels (K2P ,“leak” K+ channels) (Coetzee et al,
1999). A multitude of potassium channel subunits, their post-translational
modifications, heterogeneous distribution in the nervous system, and their
differential subcellular localization facilitate enormous variability in the electrical
properties of neurons (Vacher et al, 2008). The wide variety of possible subunit
combinations and accessory proteins extends the diversity of neuronal phenotypes
even further.
Kv channels are encoded by 40 genes in humans, which are divided into 12
subfamilies, named Kv1 - Kv12, based on relative sequence homology (Coetzee et
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al, 1999; Gutman et al, 2005). For the Kv channel genes, a parallel nomenclature
has been developed in official HUGO Human Gene Nomenclature, where they
are  named  KVNx,  with  a  changed  fourth  letter  ‘x’  (Bruford  et  al,  2008).  The
original four gene families were assigned the letters A-D (Kv1-Kv4 = KCNA-
KCND), and Kv5-Kv12 families have other designations. Kv families Kv5, 6, 8,
and 9 encode subunits that act as modifiers (Gutman et al, 2005); these subunits
do not produce functional channels on their own. Instead, they form
heterotetramers with Kv2 family subunits, increasing functional diversity within
this family.
Kv channels are composed of four principal subunits (α-subunits). The four
α-subunits are arranged around a central pore as homotetramers or
heterotetramers. A single α-subunit is a multi-transmembrane protein containing
six transmembrane segments (S1-S6) and a membrane re-entering P-loop between
segments S5 and S6. The ion-conducting pore is lined by S5-P-S6 sequences from
each of the four subunits. The four S1-S4 segments, each containing four
positively charged arginine residues in the S4 segment, act as voltage sensor
domains and gate the pore. Schematic representation of the domain structure and
the tetrameric organization of Kv channels is presented in Figure 4. Reviewed in
(Wulff et al, 2009; Yellen, 2002)
Figure 4. Domain structure and the tetrameric organization of Kv channels. Schematic
representation of the tetrameric organization of a Kv channel. The right panel represents
a single Kv channel ɲ-subunit consisting of six transmembrane segments (S1-S6) and an
intracellular NH2 and COOH terminus. Left panel represent a top view of Kv tetramer in
which the four subunits are arranged around a central pore. Reprinted from (Bocksteins
& Snyders, 2012). Copyright © 2012, The American Physiological Society.
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Voltage-gated potassium (Kv) channels open in response to changes in
membrane potential and permit the selective flow of potassium ions across the
membrane. Due to the concentration gradient of K+ that exists across the cell
membrane, the opening of Kv channels results in an efflux of positive charge,
which can serve to repolarize or even hyperpolarize the membrane. Activation of
Kv channels in excitable cells, such as neurons or cardiac myocytes, thus reduces
excitability, whereas channel inactivation has the opposite effect and increases the
excitability. In excitable cells, Kv channels are for instance responsible for
repolarization after action potential firing. In both excitable and non-excitable
cells, Kv channels also play an important role in Ca2+ signaling, volume regulation,
secretion, proliferation, and migration. Kv channels often form a part of large
multimolecular complexes. The function of these complexes may also be
influenced by the channel through mechanisms not involving ion-conduction.
(Wulff et al, 2009)
1.4.2 Auxiliary subunits of voltage-gated potassium channels
Voltage-gated potassium channels do not exist as independent units merely
responding to changes in membrane potential but function as multimolecular
complexes able to integrate a variety of signals regulating the channel activity (Li et
al, 2006; Pongs & Schwarz, 2010). The channel complex frequently contains
auxiliary subunits that are diverse in structure and function. Proteins that associate
with K+ channels may do so dynamically or they may be constitutively complexed
with the channel protein. Auxiliary subunits affect the channel gating as well as the
expression, subunit composition, or localization of the channel complex (Li et al,
2006). In addition, auxiliary subunits may link channel function to intra- or
extracellular  signals,  and  many  of  them  have  been  shown  to  affect  the
pharmacological properties of the channel (Bett & Rasmusson, 2008; Sesti et al,
2000). The significance of auxiliary subunits is demonstrated in humans and in
experimental animals by several associated diseases, such as arrhythmogenesis,
hypothyroidism, hypertension, periodic paralysis, sensorineural deafness, and
epilepsy (Abbott et al, 1999; Abbott et al, 2001; Brenner et al, 2000; Brenner et al,
2005; Duggal et al, 1998; Roepke et al, 2009; Schulte et al, 2006; Schulze-Bahr et al,
1997; Splawski et al, 1997). So far, auxiliary subunits have been identified only for
a portion of the large group of Kv channel α-subunits. The role of KCNE
subunits in Kv channel function in mammalian heart and skeletal muscle has been
widely demonstrated (Abbott et al, 1999; Abbott et al, 2001; Barhanin et al, 1996;
Sanguinetti et al, 1996; Splawski et al, 1997; Tyson et al, 1997). In neurons, the best
known auxiliary subunits of Kv channels include the cytoplasmic β-subunits for
the Kv1 channels, KchIPs, and DPPLs for the Kv4 channels (An et al, 2000;
Nadal et al, 2003; Rettig et al, 1994; Scott et al, 1994).
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1.5 Kv2.1
1.5.1 Domain structure of Kv2.1
Voltage-gated potassium channel α-subunit Kv2.1 is a protein of 857 amino acids
in humans. The domain structure of Kv2.1 consists of six transmembrane
segments (S1-S6) and large cytoplasmic N- and C-terminal domains (Figure 5)
(Frech et al, 1989). The membrane-spanning S1–S6 domains comprise approx.
25% of the polypeptide, and form the voltage-sensing and K+ ion-selective pore
components of the channel.
The Kv2.1 polypeptide is distinguished among K+ channels by its unusually
long (441-amino acid) cytoplasmic C-terminus. Almost 75% of Kv2.1 protein is
cytoplasmic, with the cytoplasmic C-terminus comprising over 50% of the Kv2.1
α-subunit. The cytoplasmic N-terminus contains the tetramerization (T1) domain
that is required for the assembly of α subunits into a functional tetrameric channel.
The cytoplasmic C-terminus contains the sequence required for specific subcellular
localization of Kv2.1 protein (PRC, proximal restriction and clustering signal). The
large intracellular regions can mediate interactions with diverse cellular
components, and can be targeted by cellular enzymes (e.g. protein kinases and
phosphatases) to achieve reversible modification of channel structure and
function. (Misonou et al, 2005b)
The only extracellular parts of the Kv2.1 protein are between the
transmembrane segments. Kv2.1 amino acid sequence contains a single consensus
N-linked glycosylation site on the extracellular S3-S4 linker domain (Frech et al,
1989). However, the native brain Kv2.1 channels and recombinant Kv2.1 channels
expressed in heterologous systems, are not N-glycosylated (Shi & Trimmer, 1999).
1.5.2 Kv2.1 gene KCNB1
The human gene coding for Kv2.1 is called KCNB1 and  it  is  located  in
chromosome 20 at 20q13.2 (Melis et al, 1995). The KCNB1 gene  has  a  simple
structure: it contains only a single large (107 kb) intron in the region encoding the
beginning of the S1-S6 core domain. De novo mutations in KCNB1 have been
identified in epileptic encephalopathy (Torkamani et al, 2014). Single-nucleotide
polymorphism in KCNB1 has been associated with increased cardiac left
ventricular mass (Arnett et al, 2009). Interestingly, two individuals homozygous for
a KCNB1 variation substituting the penultimate amino acid serine 857 with
asparagine have been identified in an earlier study on the low voltage alpha EEG
trait, and one of the Asn857/Asn857 homozygotes was reported to have
schizophrenia and the other had paranoia (Mazzanti et al, 1996). However, the
association of the corresponding single nucleotide polymorphism (SNP)
rs34280195 with schizophrenia has not been studied before.
For clarity, the name KV2.1 (KCNB1) will be used for the human gene
in this study.
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1.5.3 Channel assembly of Kv2.1
Four Kv2.1 α-subunits assemble into a tetrameric channel. It has been thought
that Kv2.1 α-subunits do not form heteromultimeric channels with the other Kv2
family member, Kv2.2, in mammalian brain, since these two Kv2 α-subunits
exhibit contrasting patterns of subcellular distribution in co-expressing cells
(Hwang et al, 1993). More recently, however, it has been shown that the long form
of Kv2.2 is colocalized with Kv2.1 in a subset of cortical pyramidal neurons and
these two proteins are capable of forming functional heteromeric channels (Kihira
et al, 2010).
Several studies have suggested that the function of Kv2.1 channels can be
diversified through heteromultimerization with the “silent” Kv5, Kv6, Kv8, and
Kv9 subunits, which can modify the inactivation, trafficking, drug sensitivity, and
expression of Kv2.1 (Bocksteins & Snyders, 2012; Ottschytsch et al, 2002; Salinas
et al, 1997b). These “silent” subunits do not independently produce electrically
functional channels, but in vitro they are shown to interact with the Kv2 subfamily,
to form functional heterotetrameric channels and to modulate the Kv2 current
(Bocksteins & Snyders, 2012). However, the cellular and subcellular localization of
Figure 5. Domain structure of Kv2.1. Schematic representation of the predicted
membrane topology of a single Kv2.1 ɲ-subunit. (S1–S6) the six transmembrane
segments, (P-loop) the amino acid residues that form the bulk of the lining of the
channel pore, (T1 Dom) the tetramerization domain, (PRC) the proximal restriction
and clustering signal. Serine at position 857 (S857) is of specific interest in this
study.
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these subunits in brain is not well characterized (Vacher et al, 2008). Currently, it is
unclear how broadly these proteins associate with the Kv2.1 channel complex,
since the colocalization of these silent subunits with Kv2.1 in brain has not been
demonstrated.
1.5.4 Overall distribution of Kv2.1
Kv2.1 expression and localization has been mostly studied in rodents. It is widely
expressed in the central nervous system (Hwang et al, 1993; Klumpp et al, 1995;
Muennich & Fyffe, 2004). The localization of Kv2.1 is restricted to neurons,
including both principal neurons and interneurons (Du et al, 1998; Hwang et al,
1993; Maletic-Savatic et al, 1995; Trimmer, 1991). In the brain, the Kv2.1
distribution is so broad that Kv2.1 staining pattern resembles that of the Nissl
stain in many regions (Vacher et al, 2008). Among interneurons, Kv2.1 is found in
the majority of cortical and hippocampal parvalbumin, calbindin, and
somatostatin-containing inhibitory interneurons (Du et al, 1998). In spite of the
widespread distribution of Kv2.1, certain cells have especially prominent Kv2.1
expression. For example, cortical pyramidal neurons in layers II/III and layer V
are especially striking for their high levels of Kv2.1 expression (Hwang et al, 1993;
Misonou & Trimmer, 2004; Rhodes et al, 1995). Kv2.1 is also present at high
levels in the hippocampus, especially in CA1 pyramidal cells and dentate granule
cells (Vacher et al, 2008).
In peripheral  nervous system, Kv2.1 is  expressed in DRG neurons (Kim et
al, 2002). Outside the nervous system, Kv2.1 is also reported to be expressed in
cardiac, skeletal and smooth muscle, as well as in pancreatic β-cells (Patel et al,
1997; Van Wagoner et al, 1997; Yan et al, 2004).
1.5.5 Subcellular localization of Kv2.1
The subcellular localization of Kv2.1 in neurons is fascinating. In spite of a broad
expression in brain, within individual neurons the localization of Kv2.1 is highly
restricted. Kv2.1 is specifically localized to unique micron-sized clusters at
perisomal plasma membrane, including cell soma, proximal dendrites and axon
initial segment (Figure 6, control conditions). Several studies have demonstrated
that Kv2.1 localizes to cell soma and the proximal part of dendrites (Du et al,
1998; Hwang et al, 1993; Maletic-Savatic et al, 1995; Rhodes et al, 1995; Scannevin
et al, 1996; Trimmer, 1991), but not to axons and synaptic terminals (Du et al,
1998; Scannevin et al, 1996; Trimmer, 1991). However, more recently Kv2.1 is
shown to also be localized in the axon initial segment of several neuronal types
(King et al, 2014; Sarmiere et al, 2008).
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1.5.6 Kv2.1 clusters
The physiological role of Kv2.1 clusters is still largely unknown. Until now, only
the pore forming α-subunits Kv2.1 and Kv2.2 have been localized to these plasma
membrane sites in brain (Kihira et al, 2010; Trimmer, 1991). However, Kv2.2
expression in brain is much more restricted than the ubiquitous expression of
Kv2.1 (Hermanstyne et al, 2010; Kihira et al, 2010). In cortex, Kv2.2 is expressed
only in a subset of pyramidal neurons, where it is shown to colocalize with Kv2.1
(Kihira et al, 2010).
Several studies have addressed the question of what are the possible intra-
and extracellular structures associating with Kv2.1 clusters. Kv2.1 clusters at the
Figure 6. Localization and stimulus-induced dispersion of Kv2.1.  (a) Glutamate-induced
dispersion of Kv2.1. In control conditions, Kv2.1 is localized to large clusters on the plasma
membrane of the soma and proximal dendrites in cultured hippocampal neurons.
Stimulation  with  glutamate  (10  μM  for  10  min)  results  in  translocation  of  Kv2.1  from
clusters to a more uniform distribution on the membrane. Kv2.1 (green) and dendritic
marker AP-2 (red). Reprinted by permission from Macmillan Publishers Ltd: Nature
Neuroscience 7: 711-718, Misonou et al, 2004, copyright © 2004.
http://www.nature.com/neuro/index.html (b) CO2-induced dispersion of Kv2.1. In control
conditions, Kv2.1 is localized to large somatodendritic clusters in rat brain (subiculum).
Hypoxia/ischemia induced by CO2 inhalation (2 min) results in Kv2.1 translocation such that
Kv2.1 staining is uniform on the surface membrane. Republished with permission of
Society  for  Neuroscience,  from  Misonou  et  al,  2005a,  copyright  ©  2005;  permission
conveyed through Copyright Clearance Center, Inc.
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plasma membrane are shown with electron microscopy to lie over ER-derived
structures called subsurface cisterns (SSC) (Du et al, 1998; Mandikian et al, 2014).
These  membrane  discs  are  rich  in  Ca2+ releasing channels inositol triphosphate
receptors (IP3R) and ryanodine receptors (RyR) and are very closely associated
with plasma membrane (Berridge, 1998; Rosenbluth, 1962). Also in cultured
hippocampal neurons, Kv2.1 clusters are shown to partly colocalize with clusters
of intracellular RyRs (Antonucci et al, 2001; Misonou et al, 2005b). Kv2.1 clusters
on the axon initial segment are also found near RyR-rich cisternal organelles (King
et al, 2014). Recently, coupling of Kv2.1 channels and RyRs has been studied in
more detail (Mandikian et al, 2014). Kv2.1 clusters are found juxtaposed to RyR
clusters in neurons in specific brain regions, and this is especially prominent in
striatal medium spiny neurons (MSN).
In the extracellular space, Kv2.1 clusters clearly appose cholinergic synapses
in spinal motor neurons (Muennich & Fyffe, 2004). However, in cortical and
hippocampal neurons Kv2.1 clusters are not associated with synapses (Du et al,
1998; Misonou et al, 2008; Mulholland et al, 2008). In cortical pyramidal neurons,
Kv2.1 clusters are shown to reside in extrasynaptic areas (Misonou et al, 2008) and
to be faced by astrocytic processes (Du et al, 1998; Misonou et al, 2008).
Interestingly, Kv2.1 localization is regulated so that several stimuli, such as
increased neuronal activity and ischemia, are able to induce declustering of the
Kv2.1 channel (Figure 6) (Misonou & Trimmer, 2004; Misonou et al, 2005a).
Following stimulus, Kv2.1 is diffusely distributed at the neuronal plasma
membrane, but the localization remains restricted to the soma and proximal part
of neurites. These mechanisms are reviewed in more detail in chapter 1.5.8.
The restricted localization of Kv2.1 is also retained when neurons are
cultured. In cultured hippocampal neurons about 20 percent of somal surface was
occupied with Kv2.1 clusters at 14 DIV (Fox et al, 2013). Kv2.1 can also form
clusters even when heterologously expressed in HEK293 cells or MDCK cells
(Mohapatra & Trimmer, 2006; O'Connell & Tamkun, 2005).
A number of studies have focused on defining the determinants of the
characteristic subcellular distribution of Kv2.1 (Antonucci et al, 2001; Lim et al,
2000; Scannevin et al, 1996). Deletion analysis of Kv2.1 has revealed a segment of
about 25 amino-acids in the C-terminus (amino acids 573-598) that is necessary
and sufficient for the proximally restricted and clustered localization (Lim et al,
2000). The segment is termed PRC signal. Within this segment, four residues were
found to be especially important for the clustered localization; Ser583, Ser586,
Phe587, and Ser 589 (Lim et al, 2000). It is noteworthy that three of these residues
are serines, since the phosphorylation and clustering of Kv2.1 are shown to be
coupled (Misonou et al, 2004).
The trafficking mechanism of Kv2.1 to distict dendritic subcompartments
has been studied recently (Jensen et al, 2014). Kv2.1 channels are sorted into
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specific transport vesicles at the Golgi apparatus and subsequently trafficked
through a mechanism involving myosin IIB (Jensen et al, 2014).
The mobility of Kv2.1 has been studied in cultured cells with live cell
imaging using FRAP (fluorescence recovery after photobleaching) and quantum
dot-tracking experiments (Deutsch et al, 2012; O'Connell et al, 2006; Tamkun et al,
2007). Kv2.1 channels are delivered into the cell surface clusters via trafficking
vesicles. Following insertion, Kv2.1 is retained in the surface cluster. However,
within the surface cluster, the Kv2.1 channel is freely mobile. The clusters
themselves  are  able  to  move  short  distances  (less  than  2  μm in  several  minutes).
Clusters do not make any large-scale movements, remaining roughly within the
same membrane area. Clusters are able to fuse to form larger structures, as well as
break apart generating smaller structures. Generally, Kv2.1 channels outside the
clusters ignore the cluster boundary, readily diffusing through these microdomains.
However some non-clustered channels (5% of studied cases) become retained
within the cluster. These findings are consistent with the idea that Kv2.1 is
retained in the cluster by its association with the underlying subsurface cistern.
It  has  been  suggested  that  Kv2.1  clusters  are  insertion  platforms  for  ion
channel delivery to the plasma membrane (Deutsch et al, 2012). Deutsch et al.
suggest that Kv2.1 clusters function as specialized cell-surface microdomains
involved in membrane-protein trafficking.
1.5.7 Function of Kv2.1 in nervous system
Kv2.1 channels constitute an essential component of the delayed rectifier current
(IK) and regulate excitability in several neuronal types (Baranauskas et al, 1999; Du
et al, 2000; Guan et al, 2007; Malin & Nerbonne, 2002; Mohapatra et al, 2009;
Murakoshi & Trimmer, 1999). Sustained outward potassium current is greatly
reduced by intracellular application of the Kv2.1 antibody in cultured hippocampal
neurons (Murakoshi & Trimmer, 1999) or by antisense treatment against Kv2.1 in
cultured hippocampal slices (Du et al, 2000), indicating that Kv2.1 is a major
contributor of the delayed rectifier currents. In particular, Kv2.1 has been shown
to regulate excitability during periods of high-frequency firing in hippocampal
pyramidal cells or tonic firing in sympathetic neurons (Du et al, 2000; Malin &
Nerbonne, 2002). In cortical pyramidal cells, Kv2.1 has been shown to underlie
the slowly inactivating potassium current (Guan et al, 2007) and to regulate the
firing rate and inter-spike interval during repetitive firing (Guan et al, 2013).
1.5.8 Dynamic modulation of Kv2.1
Kv2.1 has up to 60 putative phosphorylation sites and it is strongly regulated by
phosphorylation (Misonou et al, 2006; Murakoshi et al, 1997; Park et al, 2006;
Tiran et al, 2003). At least 34 in vivo phosphorylation sites have been identified to
date (Park et al, 2006; Trimmer, 2014). Kv2.1 is also modified by SUMOylation
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(Plant et al, 2011). These modifications strongly affect the localization and
function of Kv2.1.
The phosphorylation, localization, and function of Kv2.1 are coupled.
Under normal conditions, Kv2.1 is highly phosphorylated (Misonou et al, 2006)
and localized to characteristic somatodendritic clusters (Du et al, 1998; Hwang et
al, 1993; Rhodes et al, 1995; Scannevin et al, 1996; Trimmer, 1991). Increased
neuronal activity, induced by kainate seizures in vivo or glutamate stimulation in
vitro, leads to dephosphorylation of Kv2.1 and dispersion of clustered Kv2.1 to
diffuse somatodendritic localization (Misonou et al, 2004; Misonou et al, 2006).
These modifications are associated with a large hyperpolarizing shift in voltage-
dependent activation of Kv2.1 in vitro and neuronal IK in vivo,  which  is  able  to
suppress neuronal activity (Misonou et al, 2004; Misonou et al, 2006; Mohapatra et
al, 2009). Additionally, a reduction of neuronal activity, by activity blockade in vitro
or with anesthetics in vivo, leads to hyperphosphorylation of Kv2.1, suggesting that
the regulation of Kv2.1 is bidirectional (Misonou et al, 2006). Based on these
studies, it has been suggested that Kv2.1 acts as an adjustable resistor in neuronal
soma, providing a mechanism of homeostatic plasticity (Misonou et al, 2005b;
Surmeier & Foehring, 2004).
The major protein phosphatase known to modulate Kv2.1 channel is the
Ca2+ and calmodulin-dependent protein phosphatase calcineurin (protein
phosphatase 2B, PP2B) (Misonou et al, 2005a; Misonou et al, 2006). Modifications
in phosphorylation, localization, and activity of Kv2.1 by glutamate stimulation are
thought to be mediated through NMDA receptor activation, followed by elevated
cytosolic Ca2+ levels (Figure 7). Increase in intracellular Ca2+ results in activation of
calcineurin, which then dephosphorylates Kv2.1 channels. As described above,
dephosphorylation of Kv2.1 is coupled to dispersion and alterations in voltage-
dependent activation.
Hypoxia/ischemia, produced by CO2 treatment in vivo or chemically-induced
experimental ischemia in vitro, elicits a similar dephosphorylation and dispersion of
Kv2.1 (Misonou et al, 2005b; Misonou et al, 2008). Consequently, Kv2.1 is
suggested to function as a mechanism to suppress pathological hyperexcitability of
centralneurons during ischemic conditions.
Work  performed  in  cultured  HEK293  cells  has  demonstrated  that  the
insertion of the cytoplasmic C-terminal domain of Kv2.1 to diverse Kv channels is
sufficient to transfer Kv2.1-like clustering, and dynamic modulation of localization
and voltage-dependent activation to these channels (Mohapatra & Trimmer, 2006).
PRC (proximal restriction and clustering) signal was sufficient for the clustered
localization, but not for the modulation of clustering (Mohapatra & Trimmer,
2006).
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1.5.9 Functions of Kv2.1 unrelated to K+ conductance
Kv2.1 has also been implicated in non-traditional Kv channel functions. Kv2.1 is
suggested to play a role in vesicular release (exocytosis) in both neurosecretory
cells and sensory neurons (Feinshreiber et al, 2009; Feinshreiber et al, 2010). Kv2.1
binds to both syntaxin and SNAP25 in vitro and thus has been postulated to be
directly involved in membrane fusion events (Michaelevski et al, 2003).
It has been suggested that a significant portion of Kv2.1 channels at
the  cell  surface  exist  in  a  non-conducting  state  (Fox  et  al,  2013;  O'Connell  et  al,
2010), and the non-conducting state depends on the density of Kv2.1 channels
(Fox et al, 2013). Kv2.1 is suggested to form insertion platforms for delivery of
membrane proteins including other Kv ion channels to the plasma membrane
(Deutsch et al, 2012). Kv2.1 has also been suggested to play a structural role in the
remodeling of the cortical endoplasmic reticulum (cER) (Fox et al, 2015).
Figure 7. Regulation of Kv2.1 channels. It is suggested that calcium entry through
ionotropic glutamate (NMDA) receptors, voltage-dependent calcium channels (VCC) or
intracellular calcium release activates calcineurin (PP2B), leading to the dephosphorylation
and dispersal of Kv2.1 clusters in hippocampal pyramidal neurons. Reprinted by permission
from Macmillan Publishers Ltd: Nature Neuroscience 7: 691-692, Surmeier et al, 2004,
copyright © 2004. http://www.nature.com/neuro/index.html
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1.5.10 Kv2.1 deficient mice
A study of behavioral and neurological phenotypes of Kv2.1-deficient mice has
recently been published (Speca et al, 2014). The study reported that deletion of
Kv2.1 leads to neuronal and behavioral hyperexcitability. Kv2.1 deficient mice
display reduced body weight compared to wildtypes, but no significant changes in
brain  anatomy  are  evident.  No  alteration  in  the  expression  of  several  related  Kv
channels in Kv2.1 KO brains is reported. Kv2.1 KO mice are hyperactive and they
display impaired spatial learning, failing to improve performance in the Morris
water maze. They also exhibit repetitive jumping and rearing when transferred to a
new cage.
The effect of Kv2.1 deletion on delayed rectifier current IK was  studied  in
cultured hippocampal neurons derived from Kv2.1 KO mice. The difference
between IK recorded  from  KO  and  WT  neurons  was  surprisingly  modest
considering the established role of Kv2.1 as a significant component of IK in
several cell types. However, the slowly deactivating component of IK was shown to
be reduced in Kv2.1 KO neurons. (Speca et al, 2014)
Kv2.1 deficient mice experience handling-induced seizures and are
susceptible to chemically induced seizures. Specifically, Kv2.1 deficient mice
display accelerated seizure progression in response to flurothyl-induced epileptic
seizures and are also more susceptible to pilocarpine-induced seizures. In addition,
recordings from hippocampal slices revealed increased responses to convulsant
bicuculline. (Speca et al, 2014)
Kv2.1 deficient mice also show reduced fasting blood glucose levels and
elevated serum insulin levels due to altered glucose-stimulated electrical activity in
pancreatic β cells (Jacobson et al, 2007).
1.5.11 Physiological and pathophysiological roles of Kv2.1
In the mammalian brain, Kv2.1 is thought to function as a homeostatic suppressor
of elevated neuronal activity (Misonou et al, 2004; Misonou et al, 2005b; Misonou,
2010; Mohapatra et al, 2009; Speca et al, 2014; Surmeier & Foehring, 2004) and as
a mechanism to suppress pathological hyperexcitability of central neurons during
ischemic conditions (Misonou et al, 2005a; Misonou et al, 2008). In DRG neurons,
Kv2 downregulation is suggested to contribute to hyperexcitability in chronic pain
(Ishikawa et al, 1999; Kim et al, 2002; Tsantoulas et al, 2014).
In addition to regulating excitability in nervous system, Kv2.1 regulates
cardiac ventricular repolarization (Xu et al, 1999), insulin secretion by pancreatic β-
cells (Herrington et al, 2006; Li et al, 2013; MacDonald et al, 2002), and hypoxic
pulmonary vasoconstriction (Archer et al, 1998; Patel et al, 1997). In cerebral
artery smooth muscle, Kv2.1 also regulates myogenic constriction (Amberg &
Santana, 2006).
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1.6 Schizophrenia
1.6.1 Characteristics of schizophrenia
Schizophrenia is a devastating psychiatric illness producing great suffering for
patients and also for their family members. Although general-population incidence
estimates  vary,  it  appears  to  affect  0.5-1%  of  people  worldwide.  It  is  one  of  the
most important public health problems in the world. Heterogeneity is a hallmark
of schizophrenia and there is considerable variation between patients (MacDonald
&  Schulz,  2009;  Tandon  et  al,  2009).  In  fact,  it  is  now  widely  accepted  that
schizophrenia likely includes multiple phenotypically overlapping disease entities
or syndromes (Keshavan et al, 2011).
Characteristics of schizophrenia can be divided into three categories:
positive symptoms, negative symptoms, and cognitive problems. The term
“positive symptoms” refers to symptoms that are in excess of or distortions of
normal functions – additions to normal thoughts, emotions, or behaviors (Weiden
et al. 1999). These include hallucinations (typically auditory), delusions and thought
disorders. The term “negative symptoms” refers to absence or reduction of normal
emotions and behaviors. These include, for instance, alogia (poverty of speech),
affective flattening (reduction of emotional expressiveness), anhedonia (inability to
experience pleasure), avolition (lack of motivation), and apathy (general lack of
interest). Cognitive deficits, although not diagnostic criteria, are considered as core
features of schizophrenia. These include, for instance, deficits in working memory,
attention, verbal learning and memory, information processing, and executive
functioning. Mood symptoms can also occur in schizophrenia.(Tandon et al, 2009)
Schizophrenia can be described by sequential trajectory, including premorbid
phase, prodromal phase, firs psychotic episode, repeated episodes of psychosis
with inter-episode-remission, and stable phase (Tandon et al, 2009). There is
enormous variation in the progression of the illness across patients, however.
Psychotic symptoms lead to diagnosis, but patients usually experience other
symptoms before the first acute phase of the disorder. These symptoms may exist
for a few days or several years. Symptoms preceding the first acute phase are non-
specific to schizophrenia, and similar symptoms are experienced in other
psychiatric disorders. These include neurotic symptoms (e.g. anxiety), mood
symptoms (e.g. depression), cognitive symptoms (e.g. difficulties to concentrate),
perceptional symptoms, apathy, sleep disturbances, and behavioral changes (e.g.
suspiciousness, social withdrawal) (Yung & McGorry, 1996). The onset of
psychotic symptoms is usually during adolescence or early adulthood (MacDonald
& Schulz, 2009). The age of onset is earlier in males. The initial decade of illness is
generally marked by variable episodes of psychosis and inter-episode remission.
Finally, in the stable phase psychotic symptoms are less prominent and negative
symptoms and cognitive deficits become increasingly prominent (Tandon et al,
2009). Recovery of varying degrees can occur at any stage of the illness.
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Schizophrenia is multifactorial in nature with contributions from multiple
susceptibility genes and environmental risk factors. Currently, schizophrenia is
widely considered as a neurodevelopmental disorder. However, the disease
mechanism is poorly understood.
1.6.2 Genetics of schizophrenia
Schizophrenia is highly heritable and genetic factors contribute about 65-80% of
liability to the illness (Lichtenstein et al, 2009; Sullivan et al, 2003). However, the
genetic etiology is complex and remains largely unknown. Before the GWAS
(genome wide association study) era, linkage analysis, and association studies of
candidate genes have revealed a large number of susceptibility regions and genes.
Among the most widely studied associated genes are e.g. DISC1 (disrupted  in
schizophrenia 1), DTNBP1 (dysbindin), NRG1 (neuregulin 1), GRM3 (glutamate
receptor, metabotropic 3), and COMT (catechol-O-methyl-transferase) (Chubb et
al, 2008; Harrison et al, 2008; Lewandowski, 2007; Li & He, 2007; Munafò et al,
2008). However, even for the most promising genes, there has been a lack of
consistency in implicating particular alleles as liable for schizophrenia (Sanders et
al, 2008). In recent years, substantial progress in understanding the genetic
architecture of schizophrenia has come primarily through large-scale genomic
approaches.
Genetic risk of schizophrenia is polygenic, each genetic variant contributing
a small increment of risk (Purcell et al, 2014; Ripke et al, 2013). The risk is also
heterogeneous across individuals, and the risk variant combinations may differ
substantially between affected individuals, especially between families not sharing
the same ancestry. Many of the risk-associated genetic variants for schizophrenia
also contribute to the risk of other neuropsychiatric disorders, such as bipolar
disorder, autism, depression, and attention-deficit hyperactivity disorder (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013; International
Schizophrenia Consortium, 2009). Risk variants range in frequency from common
to extremely rare (Sullivan et al, 2012). The existing findings account for only a
minority of the heritability of schizophrenia, and several factors may contribute to
the “missing heritability”, including yet unidentified common or rare variants,
gene-gene interactions, and epigenetic factors (Harrison, 2015).
Patients with schizophrenia have an increased burden of large (over 100 kb)
rare  (frequency  less  than  1  %)  copy  number  variants  (CNVs)  compared  with
controls. They also have an increased frequency of de novo CNVs  (Kirov  et  al,
2012; Xu et al, 2008). CNVs in several distinct genomic regions have been
associated with increased risk of schizophrenia. In general, schizophrenia-
associated CNVs have large individual effect sizes but are extremely rare in the
population. The effect of these CNVs is not specific to schizophrenia. The same
CNVs are associated with other neurodevelopmental or psychiatric disorders.
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However, studies on CNVs, especially de novo CNVs, have gained insights into
biological processes disturbed in schizophrenia. CNVs are enriched for genes in
the postsynaptic density, particularly genes of the NMDA receptor complex,
calcium-channel-signaling genes and targets of the fragile X mental retardation
protein (FMRP) (Kirov et al, 2012; Szatkiewicz et al, 2014).
The major histocompatibility complex (MHC) region, harboring several
genes involved in the immune system and autoimmunity, has been associated with
schizophrenia in several studies (International Schizophrenia Consortium, 2009;
Ripke et al, 2013; Schizophrenia Psychiatric Genome-Wide Association Study
Consortium, 2011; Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014; Shi et al, 2009; Stefansson et al, 2009).
The largest GWAS to date was published in 2014 and included almost 37
000 patients with schizophrenia and 113000 controls from 40 different research
centers, together forming the Psychiatric Genomics Consortium (PGC)
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).
This was the largest molecular genetic study of schizophrenia, or indeed of any
neuropsychiatric disorder, ever conducted. Meta-analysis of these datasets
identified 108 genetic loci associated with schizophrenia. These 108 genomic
regions included 25 previously reported and 83 novel loci. One associated locus
contains the dopamine receptor D2 (DRD2) gene. Other genes especially noted
were voltage-gated calcium channels (CACNA1C, CACNA1I, and CACNB2) and
many genes involved in glutamatergic neurotransmission and synaptic plasticity
(e.g. GRIA1, GRIN2A and GRM3, SRR). In addition to genes expressed in brain,
the associations were enriched for genes expressed in tissues involved in immunity,
supporting the role of immune dysregulation in schizophrenia. Concerning our
study, the most interesting finding was that one schizophrenia-associated locus
contained KCNB1 (encoding Kv2.1) and PTGIS genes. In addition, another
associated locus contains KCNV1, the gene encoding Kv8.1 potassium channel
subunit, which is able to interact with Kv2.1. GWAS only implicate regions,
however, not genes. The associated 108 loci contain about 600 genes, and it is
unclear which of these genes are the real susceptibility genes for schizophrenia and
what are the real causal variants.
Enormous advances in sequencing technology have allowed exome
sequencing studies detecting rare variants, SNPs, and small insertions or deletions
(indels), which might contribute to schizophrenia (Fromer et al, 2014; Purcell et al,
2014). No single rare allele was associated at genome-wide levels of significance;
however, significant enrichments for rare disruptive SNPs and indels were found
in  proteins  affiliated  with  ARC  and  NMDAR  genes,  FMRP-targets,  and  voltage-
gated calcium channels.
The knowledge of underlying genes can help to understand the
pathophysiology of schizophrenia and to develop more accurate diagnostic
procedures and treatment options. Converging evidence is now emerging from
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several advanced genetic research strategies implicating biological pathways such as
immune function and the MHC locus, NMDA receptor signaling, and calcium
signaling in schizophrenia (International Schizophrenia Consortium, 2009; Ripke
et al, 2013; Schizophrenia Psychiatric Genome-Wide Association Study
Consortium, 2011; Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014; Shi et al, 2009; Stefansson et al, 2009). Defects in postsynaptic
components of glutamatergic synapses and mechanisms of synaptic plasticity are
now widely implicated in the pathogenesis of schizophrenia (Hall et al, 2015;
Kirov et al, 2012; McCarroll & Hyman, 2013; Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014).
1.6.3 Environmental risk factors of schizophrenia
Several environmental factors of small effect are associated with increased risk of
developing schizophrenia. The environmental risk factors include, for instance,
migrant status, older paternal age, Toxoplasmosis gondii antibodies, prenatal infection,
famine, cannabis abuse, obstetric and perinatal complications, urbanicity, and
winter/spring birth (Brown et al, 2005; Cannon et al, 2002; Davies et al, 2003;
Malaspina et al, 2001; McGrath et al, 2004; Mednick et al, 1988; Penner & Brown,
2007; Semple et al, 2005; Susser et al, 1996).
A range of obstetric and perinatal complications have been linked to risk of
developing schizophrenia in the offspring. Although the precise mechanisms have
not been delineated, fetal hypoxia is most commonly cited as the mediating factor
(Zornberg et al, 2000). Predisposing genetic factors might interact with hypoxia in
increasing the risk of schizophrenia (Cannon et al, 2000).
1.6.4 Pharmacological treatment of schizophrenia
The introduction of chlorpromazine in the 1950s revolutionized the treatment of
schizophrenia (Carpenter & Davis, 2012; Delay et al, 1952). Since then, over 60
antipsychotic drugs have been developed (Tandon et al, 2010). The one
pharmacological property shared by all currently-available antipsychotic drugs,
except aripiprazole, is their ability to block the dopamine D2 receptor (Carpenter
& Koenig, 2008). Although the exact mechanism of antipsychotic drugs is
unknown, these drugs are thought to block dopamine receptors in the mesolimbic
dopaminergic system to alleviate psychotic symptoms. In addition to D2 receptor,
antipsychotic drugs may have varying affinities for other receptors, including D1
receptors, several serotonin receptor subtypes (5-HT2A, 5-HT6,  and  5-HT7), α1-
adrenergic receptors and muscarinic receptors (Pratt et al, 2012).
Existing medications are most effective for positive symptoms (Leucht et al,
1999; Leucht et al, 2009), but they do have limited ability to improve negative
symptoms and cognitive deficits, which often determine the level of functional
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impairment (Miyamoto et al, 2012). Despite antipsychotic medication,
schizophrenia remains a chronic illness with substantial functional impairments for
most cases. In addition, one fifth to one third of all patients with schizophrenia are
resistant to antipsychotic drug treatment (Conley & Kelly, 2001). No major
differences in efficacy have been observed across various antipsychotic agents in
meta-analysis of placebo-controlled studies (Leucht et al, 1999; Leucht et al, 2009).
However, clozapine has been shown to be more effective in treatment
resistant/refractory cases (Kane et al, 1988; McEvoy et al, 2006).
Antipsychotic medications may cause a range of serious side-effects. In
contrast to broadly similar therapeutic effects, antipsychotic agents clearly differ in
their propensity to cause different side-effects (Leucht et al; Miyamoto et al, 2012;
Tandon et al, 2010). Unwanted consequences of dopamine-receptor blockage are
the possible extrapyramidal side effects caused by dopamine blockade in the
nigrostriatal system. The extrapyramidal side effects include tardive dyskinesia
(involuntary, repetitive movements), Parkinsonism, dystonia, and akathisia (motor
restlessness). Other possible side-effects of antipsychotics include, for instance,
metabolic adverse effects, cardiac arrhythmias, sedation, prolactin elevation, and
related sexual dysfunction, hypotension, and anticholinergic side effects (dry
mouth, constipation, blurred vision) (Tandon et al, 2010). A rare but severe
adverse effect of clozapine is agranulocytosis, which limits the more widespread
use of clozapine (Tandon et al, 2010).
Essentially, the drug treatment for schizophrenia has not advanced
substantially in the past 50 years (Carpenter & Davis, 2012). There is clearly a need
for more effective and better-tolerated drugs, which would address the various
symptom dimensions of schizophrenia.
1.6.5 Endophenotypes of schizophrenia
Reducing complex disorders into components with clear genetic connection is
described as an endophenotype strategy. Endophenotypes or “intermediate
phenotypes” are measurable, hereditary characteristics/deficits that are associated
with a specific disorder. Endophenotype can be a physiological, biochemical,
anatomical, behavioral, or a cognitive feature. They are not seen by the unaided
eye  and  are  assessed  by  experimental,  laboratory-based  methods  rather  than  by
clinical observation. They are assumed to involve the same biological pathways as
the disorder but to have simpler genetic architecture compared to the disorder
itself. They lie in an intermediate position between genes and clinical symptoms.
As such, they should provide substantially more power for finding disease genes.
In addition to genetic analysis, endophenotypes are utilized in the development of
animal models. (Allen et al, 2009; Gottesman & Gould, 2003; Gould &
Gottesman, 2006)
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By criteria, endophenotype must: 1) associate with illness in the population;
2) be heritable; 3) be state-independent (manifest in an individual whether illness is
active or in remission); 4) co-segregate with illness within families; and 5) be
present at higher rate in non-affected family members of patients than in the
general population (Gottesman & Gould, 2003).
The endophenotype concept has had success in schizophrenia, where
endophenotypes including impaired prepulse inhibition (PPI, a measure of sensory
motor gating deficits), eye-tracking dysfunction, and working memory deficits are
already connected to genetic polymorphisms and have enough support to be
considered as true endophenotypes of the disorder (Gould & Gottesman, 2006).
Other possible schizophrenia endophenotypes include alterations in different
electrophysiological measurements of the brain activity, such as event-related
potentials P50, P300, and mismatch negativity (MMN) (Turetsky et al, 2007). Many
other markers, for instance abnormalities in sustained attention, verbal learning
and memory, spatial memory, and brain morphometric features, have been
proposed as endophenotypes of schizophrenia (Carpenter & Koenig, 2008).
Prepulse inhibition (PPI) measures sensorimotor gating, which is a process
of filtering redundant or unnecessary stimuli in the brain. Normally, an intense
sensory stimulus elicits a whole-body startle response in almost all mammals. This
rapid, intense sensory stimulus may be sound or light, or it may be tactile, such as
an air puff. When a weak stimulus (prepulse) precedes the intense stimulus by 30-
300 milliseconds, the startle response is reduced. This phenomenon is called
prepulse inhibition. Patients with schizophrenia and their unaffected relatives
show deficits in PPI (Braff et al, 1978; Braff et al, 2001; Cadenhead et al, 2000).
However, impaired PPI is not specific to schizophrenia. PPI deficits are observed
in various other neuropsychiatric disorders including bipolar disorder, obsessive
compulsive disorder, and Tourette’s syndrome (Kohl et al, 2013).
1.6.6 Rodent behaviors related to schizophrenia
Animal models are useful tools in defining pathogenesis and treatment
development for human disease. Creating adequate animal models of complex
neuropsychiatric disorders like schizophrenia represent a particularly difficult
challenge. Many of the symptoms, such as hallucinations and delusion, cannot be
convincingly ascertained in animals. Nonetheless, several characteristics of
schizophrenia, such as abnormal sensory gating, social behavior, working memory,
and executive function, have reasonable correlates in mice (Nestler & Hyman,
2010; Powell & Miyakawa, 2006). Table 1 lists mouse behaviors that are
considered potentially relevant to signs and symptoms of schizophrenia. Individual
rodent behaviors are not animal models of schizophrenia. Rather, they are critical
experimental protocols in the development and testing of animal models.
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Some measurable abnormalities in schizophrenia can be measured directly in
rodents, such as prepulse inhibition of startle (PPI). On the contrary, the positive
symptoms of schizophrenia are challenging, if not impossible, to model in mice.
As the disturbed dopamine transmission has been connected to psychotic
symptoms, these symptoms are traditionally modeled in mice with dopamine-
related behavior such as locomotor activity (Lipska & Weinberger, 2000; Pratt et
al, 2012). Non-competitive NMDA-receptor antagonists (MK-801, PCP and
ketamine) and amphetamine can cause psychosis in humans (MacDonald &
Schulz, 2009). In rodents, these psychotomimetic drugs can induce increased
locomotor activity, whereas antipsychotic drugs tend to reduce locomotor activity
(Bubenikova-Valesova et al, 2008; Yee & Singer, 2013). Although the behavioral
consequences of increased dopaminergic activity are different in humans and mice,
there may be shared components of underlying biological mechanisms. However,
several caveats exist, as the locomotor activity is a nonspecific behavior and the
equivalent of locomotor activity in humans is unclear.
Psychotomimetic drugs can exacerbate psychotic symptoms in patients with
schizophrenia (Lahti et al, 1995; Lieberman et al, 1987). Increased sensitivity to the
locomotor-activating effects of these agents in rodents loosely parallels the
increased sensitivity of patients with schizophrenia to these psychotomimetic
drugs. Thus, sensitivity to psychotomimetic drugs is considered to be another
correlate of positive symptoms (Powell & Miyakawa, 2006).
Several tests for social interaction in rodents have been developed (Powell &
Miyakawa, 2006), but many are conducted in a novel environment that invokes
exploratory and anxiety-like behaviors in addition to social behaviors complicating
the interpretation of results. Social dominance can be measured in rodents by tube
test (Powell & Miyakawa, 2006).
One of the most studied cognitive impairments in schizophrenia is
impairment in working memory. In rodents, working memory can be measured
e.g. in the eight-arm radial maze and delayed matching to place task in Morris
water maze (Powell & Miyakawa, 2006). Working memory requires the ability to
rapidly form memory traces of unique events and the ability to distinguish
currently valid information from older and already-invalid information.
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Table 1. Rodent behaviors potentially relevant to signs and symptoms of
schizophrenia
Symptom
Type
Symptom/sign of
schizophrenia
Behavioral changes in rodents
Positive Psychotic symptoms (Increased locomotor activity)
(Increased locomotor activity in response to novelty or
stress)
Sensitivity to
psychotomimetic drugs
Enhanced locomotor response to non-competitive
NMDA-receptor antagonist (MK-801, PCP, ketamine)
Enhanced locomotor response to amphetamine
Increased sensitivity to psychotomimetic drugs in
other tests (e.g. increased effect of MK-801, PCP or
ketamine in PPI test)
Negative Social withdrawal Decreased interaction with a juvenile conspecific
Decreased place preference for a caged peer
conspecific
Decreased preference for social novelty
Altered social dominance on tube test
Altered aggression behavior on resident intruder assay
Decreased nesting behavior
Altered home-cage social interaction
Anhedonia Decreased reinforcing properties of drugs of abuse and
natural rewards
Cognitive Deficits in learning and
memory
Impaired alternation in T-maze working memory task
Impaired performance in 8-arm radial maze working
memory task
Delayed non-match to sample tasks
Decreased spatial learning in Morris water maze
Decreased spatial learning in 8-arm radial maze
Attentional deficits Decreased latent inhibition
Impaired 5-choice serial reaction time task
Executive dysfunction Decreased set-shifting ability
Sensory
gating
Impaired prepulse
inhibition (PPI)
Impaired prepulse inhibition (PPI)
Modified from (Arguello & Gogos, 2006; Nestler & Hyman, 2010; Powell & Miyakawa, 2006)
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1.6.7 Existing rodent models related to schizophrenia
It is clear that any animal model of schizophrenia can capture only some aspects of
this heterogeneous disorder characterized by abnormalities in uniquely human
behaviors. Absence of any single defining symptom or consistent biological
marker and limited knowledge of underlying genetic factors hinders the
development of animal models for schizophrenia. The value of animal models lies
in them being informed approximations of isolated components of the disease. As
such, several rodent models have been developed in order to better understand
specific aspects of schizophrenia. These can be divided into genetic,
developmental, drug-induced, or lesion models (Carpenter & Koenig, 2008). Some
models also combine genetic and environmental risk factors.
A large number of genetically modified mice has been developed by
modifying schizophrenia associated genes/chromosomal regions or genes involved
in biological pathways/processes associated with schizophrenia (Carpenter &
Koenig, 2008; Pratt et al, 2012). Such mice provide insight into the neurobiological
role of specific genes in terms of behavioral phenotypes, as well as the impact of
these specific genes on downstream biological pathways and neuropathological
alterations.
Developmental models include e.g. isolation rearing, neonatal immune
challenge, maternal malnutrition, and prenatal stress models (Carpenter & Koenig,
2008). The developmental models may be most useful in combination with genetic
models as this allows the genetic-environmental interactions to be captured.
Several drug-induced models have been developed. Models based on
NMDA receptor antagonists (PCP, ketamine or MK-801) have been widely used
in rodents. In addition to producing psychosis or exacerbating psychotic
symptoms, administration of NMDA receptor antagonists in humans induces
changes closely resembling schizophrenia, also including the negative symptoms of
the disease as well as the cognitive deficits (Bubenikova-Valesova et al, 2008). In
rodents, both acute and chronic administration of NMDA receptor antagonists
has also been successful in modelling cognitive impairment as well as positive and
negative symptoms of schizophrenia (Bubenikova-Valesova et al, 2008). In
addition to these behavioral changes, chronic administration of NMDA receptor
antagonist has been reported to result in a decreased mRNA expression of enzyme
GAD67 and reduction of parvalbumin-positive interneurons (Qin et al, 1994;
Rujescu et al, 2006). These findings correlate with neuropathological findings in
patients with schizophrenia (Benes & Berretta, 2001; Hashimoto et al, 2003; Volk
et al, 2000).
Lesion models include, for instance, neonatal amygdalar lesion, neonatal
ventral hippocampal lesion, and prefrontal cortical lesion (Carpenter & Koenig,
2008).
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2. AIMS OF THE STUDY
A starting point of this study was to identify novel genes induced by the neurite
outgrowth-promoting protein HMGB1 (amphoterin). Following the identification
of AMIGO, our main goal was to understand the characteristics and function of
the AMIGO protein. We were especially interested in the role of AMIGO in
Kv2.1 channel complex and the role of AMIGO-Kv2.1 channel complex in mouse
behavioral disturbances and human psychiatric disorders. We considered KV2.1
(KCNB1) as a candidate gene for human schizophrenia and schizophrenia
spectrum disorders. The specific aims of this study were:
1) To identify novel genes induced by the neurite outgrowth promoting
protein HMGB1 (amphoterin)
2) To characterize the expression pattern of the novel gene/protein AMIGO
3) To examine the role of AMIGO in nervous system function with the help
of AMIGO KO mice
4) To understand the role of AMIGO in Kv2.1 channel complex
5) To examine the role of the AMIGO-Kv2.1 channel complex in behavioral
disturbances
6) To examine the possible association of KV2.1 (KCNB1) variant allele
(rs34280195) with human schizophrenia and schizophrenia spectrum
disorders
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3. EXPERIMENTAL PROCEDURES
The methods used in this study are listed in Table 2. Detailed description of the
materials and methods can be found in the original publications, which are
referred to by their Roman numerals.
Method Used in Author personally
involved
Crude brain membrane protein samples III III
Determination of monoamines III III
DNA constructs I,II
Electrophysiology of acute hippocampal slices III III
Electrophysiology of cultured neurons II II
HEK293 cell culture and transfection II
Histological stainings III III
Human genetic studies III
Immunocytochemistry II II
Immunohistochemistry (paraffin sections) I, II I, II
Immunohistochemisty (cryosections) II, III II, III
Immunoprecipitation II
In situ hybridization I
Knockout mouse production III
Lentivirus production and transfection II
Microscopy and image acquisition I, II, III I, II, III
Mouse behavioral studies III
Ordered differential dispay I
Primary neuron culture I, II II
Protein samples from brain tissue I, II I, II
RT-PCR I
Treatments of primary neurons II II
Western blotting I, II, III I, II, III
Table 2. Methods used
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4. RESULTS
4.1 AMIGO is a novel neuronal LRR protein (I, II)
4.1.1 Identification of AMIGO
A starting point of this study was to identify novel genes induced by the neurite
outgrowth-promoting protein HMGB1 (amphoterin). With ordered differential
display (ODD), the mRNA expression was compared in cultured hippocampal
neurons growing on a surface coated with either HMGB1 or another neurite
outgrowth promoting protein laminin (I: Figure 1). A novel gene was found with
induced  expression  on  HMGB1  (amphoterin)  surface,  and  was  named  AMIGO
(amphoterin-induced gene and ORF). Subsequently, we have studied the
properties and function of AMIGO.
Bioinformatics revealed that the amino acid sequence of AMIGO comprises
a small cytoplasmic region, a single transmembrane domain, and an extracellular
part containing both immunoglobulin (Ig) and leucine-rich repeat (LRR) domains.
The LRR domain of AMIGO is composed of six LRRs (LRR1-6) flanked by N-
terminal and C-terminal cap regions (LRRNT and LRRCT). The domain structure
of AMIGO is presented in Figure 8.
Figure  8.  Domain  structure  of  AMIGO.
Schematic representation of the AMIGO
domain  structure.  (LRRNT)  LRR  N-
terminal cap region, (LRR 1-6) leucine
rich repeats 1-6, (LRRCT) LRR C-terminal
cap region, (IG) immunoglobulin
domain, (TM) transmembrane domain.
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AMIGO has five predicted N-glycosylation sites, two in the LRR domain
and three in the Ig domain. All of these sites are shown to be at least partially
glycosylated in HEK293 cells (Kajander et al, 2011). In mouse brain, the molecular
mass of AMIGO was around 80 kDa compared to the predicted molecular mass
of AMIGO (56 kDa), suggesting significant post-translational modifications (II:
Supplementary  Figure  S3A).  Indeed,  the  molecular  mass  of  AMIGO  in  mouse
brain samples is reduced following PGNase F treatment, indicating N-linked
glycosylation of AMIGO (Chen et al, 2012).
Sequence comparison revealed that AMIGO protein is conserved across
species. At the amino acid level, the identity between the rat and mouse AMIGO
is 95% and the murine sequences are 89% identical to human AMIGO.
Interestingly, the whole transmembrane domain and the cytoplasmic tail are 100%
identical between the murine and human AMIGOs. The function of AMIGO has
also been studied in zebrafish (Zhao et al, 2014). Zebrafish AMIGO1 shares over
50% identity in its amino acid sequence with AMIGO protein in human, mouse,
rat, xenopus, and medaka fish (Zhao et al, 2014).
4.1.2 AMIGO protein family
Following identification of AMIGO, two other genes were cloned on the basis of
their  homology  to  AMIGO  (I:  Figure  2A).  These  molecules  were  named
AMIGO2 and AMIGO3. The three AMIGO proteins encoded by these genes
comprise a novel AMIGO protein family belonging to the LRR- and Ig-
superfamilies.
All three AMIGOs share a similar domain structure. Sequence homology at
the amino acid level between AMIGO and AMIGO2/AMIGO3 is about 50%.
The most conserved regions between the three proteins are the LRRs, the
transmembrane region, and some parts of the cytosolic tail (I: Figure 2A).
Expression of the AMIGO proteins was studied in mouse tissues with RT-
PCR  (I:Figure  3A).  All  of  the  three  AMIGOs  are  expressed  in  brain.  The
expression of AMIGO2 and AMIGO3 in adult mouse tissues is more widespread
than the expression of AMIGO. The expression of AMIGO3 mRNA was
detected in all tissues studied.
4.1.3 Overall distribution of AMIGO
The  AMIGO  mRNA  expression  during  development  was  studied  with in situ
hybridization  in  mouse  embryo  (I:  Figure  3B).  A  clear  AMIGO  expression  was
detected already in the E13 mouse embryo. At this stage, the highest expression
was found in the dorsal root ganglia and in the trigeminal ganglion, with some
expression in the central nervous system.
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With RT-PCR analysis from different adult mouse tissues, AMIGO mRNA
was shown to be primarily expressed in the nervous system, including cerebrum,
cerebellum, and retina (I: Figure 3A). We have also studied the expression of
Amigo gene with lacZ reporter gene in tissues of heterozygous AMIGO knockout
mice. These studies confirmed wide expression of the Amigo gene in the nervous
system, including cerebrum, cerebellum, pons, spinal cord, dorsal root ganglia, and
sympathetic chain ganglia (data not shown). According to preliminary analysis with
NeuN and GFAP antibodies, lacZ reporter expression was limited to neurons and
was not present in astrocytes (data not shown).
In situ hybridization  studies  demonstrated  that  the  mRNA of  AMIGO was
prominently expressed in adult brain, where the most intense signal was detected
in the hippocampus (I: Figure 3B). The localization of AMIGO protein in mouse
cerebrum was further defined with immunohistochemistry. Immunostaining of
AMIGO was widely detected in mouse cerebrum (II: Supplementary Figure S2A
and C). AMIGO seemed to be present in practically all cerebral neurons. Intensity
of staining varied between different brain areas and different neuronal cell types.
Especially strong immunoreactivity was present in cortical structures. In
neocortex, the most prominent AMIGO staining was detected in the large
pyramidal neurons of layer V (II: Supplementary Figure S2E).
4.1.4 Subcellular distribution of AMIGO
Although wide in tissue level, immunostaining of AMIGO had a restricted
subcellular localization. Staining was clearly restricted to the soma and to proximal
part of neurites (II: Supplementary Figure S2E and G). In the large pyramidal cells
of the neocortex, the staining extended along the apical dendrite more distally
from the soma than in any other neurons studied (II: Supplementary Figure S2E
and G). At higher magnification, immunostaining revealed a distinct, punctate
pattern (II: Supplementary Figure S2G). AMIGO appeared in clusters associated
with neuronal plasma membrane.
We also studied the localization of AMIGO in neuronal primary cultures.
Similar distinctive subcellular distribution of AMIGO was preserved in cultured
hippocampal neurons (II: Figure 1C and Supplementary Figure S5A). Staining was
restricted to the peri-somatic portion of cultured neurons and the staining was
highly clustered in nature in most of the cells.
4.1.5 Temporal expression of AMIGO protein in brain
The expression of AMIGO protein during brain development was studied with
immunoblotting using mouse brain lysates from several postnatal stages (II:
Supplementary Figure S3A). AMIGO was detected with western blotting
techniques at low level after birth. The amount of AMIGO increased gradually,
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with clear increase in protein amount around two weeks after birth. The amount
of AMIGO continued to increase toward adulthood.
A similar increase in AMIGO protein amount toward adulthood was seen in
rat-brain lysates, commencing around two weeks after birth (I: Figure 4C). The rat
brain samples also demonstrated down-regulation during postnatal stages P6-P10,
which was not evident in mouse samples. The expression of AMIGO protein was
also studied during embryonic development with rat brain samples. The AMIGO
protein was detected in embryonic brain samples starting from E14 stage.
4.2 AMIGO is a component of Kv2.1 potassium channel complex (II)
4.2.1 Spatial and temporal co-expression of AMIGO and Kv2.1 potassium channel
One of the key questions in this study was to understand the distinct (wide, but
subcellularly restricted) localization of AMIGO in the nervous system. We were
fascinated to find out that similar localization has been extensively demonstrated
for the voltage-gated potassium channel Kv2.1. While Kv2.1 is widely expressed in
mouse cerebral neurons, its subcellular localization is highly restricted to large
clusters on the soma and proximal dendrites (Du et al, 1998; Hwang et al, 1993;
Rhodes et al, 1995; Scannevin et al, 1996; Trimmer, 1991). We therefore compared
the spatial and temporal expression of AMIGO and Kv2.1. Indeed, a highly
similar staining pattern was seen for Kv2.1 and AMIGO in successive histological
sections of mouse cerebrum (II: Supplementary Figure S2). The staining patterns
were identical in every brain location studied. For both proteins, the staining was
clustered in nature. In addition, western blotting revealed a parallel increase in
expression of AMIGO and Kv2.1 proteins during postnatal brain development (II:
Supplementary Figure S3).
4.2.2 Colocalization of AMIGO and Kv2.1 potassium channel
Since the spatial and temporal expression of AMIGO strongly resembled the
expression of Kv2.1 potassium channel, double immunohistochemical staining
was performed to determine their localization. Confocal microscopy revealed a
striking colocalization of AMIGO and Kv2.1 (II: Figure 1A and B). Both proteins
were  localized  to  the  same distinct  clusters  at  the neuronal perisomal membrane.
Localization of AMIGO in mouse cerebrum overlapped with that of Kv2.1 in all
brain areas studied.
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AMIGO and Kv2.1 are both expressed natively in cultured neurons (Kuja-
Panula et al, 2003; Maletic-Savatic et al, 1995). In addition to brain sections,
colocalization of AMIGO and Kv2.1 was studied in rat primary neurons. AMIGO
and Kv2.1 also colocalized extensively in cultured hippocampal neurons (Figure 9
and II: Figure 1C). In cultured cells, many of the neurons displayed clustered
staining similar to staining in neurons in vivo.
As  neurons  were  grown  in  culture,  the  AMIGO  and  Kv2.1  stain  became
gradually stronger.  Both proteins were detected in characteristic clusters in the
plasma membrane around 14 days in vitro. Even during this in vitro development,
AMIGO and Kv2.1  were  detected  simultaneously  and  in  the  same location  (data
not shown).
In addition, we transfected HEK293 cells with AMIGO and Kv2.1.
Transfected Kv2.1 is reported to form large clusters in HEK293 cells like those
seen in neurons (Mohapatra & Trimmer, 2006; O'Connell & Tamkun, 2005).
When expressed together in HEK293 cells, AMIGO and Kv2.1 colocalized
significantly (II: Figure 1D). Both proteins were localized to ring-shaped
structures. These structures resembled the clusters seen in neurons. When
transfected separately, Kv2.1 was not recognized by AMIGO antibody, and vice
versa (II: Supplementary Figure S1)
Figure 9. Colocalization of AMIGO and Kv2.1. Double-immunostaining of cultured
hippocampal neuron with AMIGO (red) and Kv2.1 (green) antibodies. The overlay of
images is presented in the right panel (merged). AMIGO and Kv2.1 exhibited striking
colocalization. Both proteins localized to clusters in the neuronal soma and the
proximal part of neurites.
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4.2.3 Association of AMIGO and Kv2.1 potassium channel
We next asked whether AMIGO associates with Kv2.1 using
immunoprecipitations with AMIGO and Kv2.1 antibodies. Immunoprecipitation
from mouse brain lysates demonstrated the association of AMIGO and Kv2.1
proteins  (II:  Figure  2  and  Supplementary  Figure  S4).  The  interaction  was
prominent in DSP-crosslinked tissue material, but it could be detected even
without crosslinking (II: Supplementary Figure S4).
As a control, the association of AMIGO with Kv1.2 in mouse brain lysates
was  also  assessed.  Kv1.2  is  another  widely  expressed  Kv  channel  α-subunit  in
brain, but the localization of Kv1.2 is predominantly axonal. No association was
seen between AMIGO and the Kv1.2 protein (II: Figure 2).
4.2.4 Stimulus-induced relocalization of AMIGO and Kv2.1
The phosphorylation stage, localization, and activity of Kv2.1 are known to be
strongly regulated. Under normal conditions, Kv2.1 is heavily phosphorylated and
its localization is clustered (Du et al, 1998; Hwang et al, 1993; Misonou et al, 2006;
Trimmer, 1991). Several stimuli are able to induce a dramatic dephosphorylation of
Kv2.1 and dispersion of Kv2.1 from clusters. Dephosphorylation and diffusion
can be induced in rat brain by kainate-induced seizures or in cultured neurons by
glutamate stimulation (Misonou et al, 2004). Similar changes are induced by CO2
treatment in rat brain or by a chemical ischemia model in cultured neurons
(Misonou et al, 2005a; Misonou et al, 2008). We were interested in the localization
of AMIGO and the interaction of AMIGO and Kv2.1 upon stimulation induced
change in Kv2.1 localization.
In cultured hippocampal neurons, a short glutamate treatment has been
shown to induce Kv2.1 dephosphorylation and dispersion of Kv2.1 from clusters
(Misonou et al, 2004; Misonou et al, 2006). We studied the localization of AMIGO
and Kv2.1 in cultured hippocampal and cortical neurons after treatment with
glutamate  (10  uM glutamate  for  15  min)  or  with  glutamate  and  NMDA receptor
blocker AP-5 (II: Supplementary Figure S5). In control conditions, a large
proportion of neurons displayed clustered staining of Kv2.1 and AMIGO. After
treatment with glutamate, most of the neurons displayed diffuse staining of Kv2.1,
as reported previously. Importantly, the glutamate treatment also dramatically
decreased the clustered staining of AMIGO. NMDA receptor antagonist AP-5 was
able to reduce the diffusion of AMIGO and Kv2.1 from clusters. In all conditions,
AMIGO and Kv2.1 colocalized in all neurons studied, whether the staining pattern
of the neuron was clustered, diffuse, or a combination of clustered and diffuse.
We also studied the distribution of AMIGO in mouse brain in response to
CO2 treatment.  Distribution  of  both  AMIGO  and  Kv2.1  was  diffuse  in  cortical
neurons of CO2-treated mice (II: Figure 2D). However, the staining of both
proteins remained restricted to the soma and the proximal part of the neurites. We
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concluded that localization of AMIGO displayed a similar, dramatic change in
response  to  CO2 treatment,  as  was  previously  reported  for  Kv2.1.  AMIGO  and
Kv2.1 colocalized in brains from CO2 treated animals as well as in brains obtained
without hypoxia.
4.2.5 AMIGO associates with Kv2.1 following stimulus-induced relocalization
AMIGO and Kv2.1 were both diffusely distributed over the proximal neuronal
plasma  membrane  in  mouse  brain  after  CO2 treatment. It was unclear, however,
whether the interaction of AMIGO and Kv2.1 was retained in diffuse localization
or whether both proteins were independently dispersed over the membrane. To
address this question, we immunoprecipitated AMIGO and Kv2.1 also from brain
lysate  of  CO2-treated mice (II: Figure 2). With western blot we confirmed the
decreased size of Kv2.1 after CO2 treatment,  previously  shown  to  be  due  to
dephosphorylation of the channel protein (Misonou et al, 2005a).
Immunoprecipitations demonstrated that AMIGO and Kv2.1 were also associated
when Kv2.1 was dephosphorylated, and both proteins were diffusely localized to
neuronal membrane.
4.2.6 AMIGO alters voltage-dependent activation of Kv2.1
To examine the effects of AMIGO on Kv2.1 channel current, we recorded ionic
currents in HEK293 cells expressing Kv2.1 either alone or together with AMIGO.
Transfected HEK293 cells have been widely used to study the Kv2.1 channel,
since the properties of the channel in transfected HEK293 cells resembles the
properties of the Kv2.1 channel in neurons (Mohapatra & Trimmer, 2006;
O'Connell & Tamkun, 2005). Transfected Kv2.1 forms large clusters and is
extensively phosphorylated, as in neurons (Mohapatra & Trimmer, 2006;
O'Connell  &  Tamkun,  2005).  In  contrast,  when  expressed  in  Xenopus  oocytes,
Kv2.1 is reported to be in a non-phosphorylated form (Misonou et al, 2005b). As
we have shown, AMIGO and Kv2.1 colocalize extensively in transfected HEK293
cells (II: Figure 1D).
Kv2.1 current is activated by membrane depolarization. No significant
difference was seen in current amplitudes at maximal membrane depolarization
(+100  mV)  when  the  Kv2.1  was  present  alone  or  with  AMIGO.  However,  the
Kv2.1 current was activated at lower (more hyperpolarized) membrane potentials,
when AMIGO was expressed with Kv2.1 (II: Figure 3).
4.2.7 AMIGO alters voltage-dependent activation of neuronal IK
Kv2.1 is an essential component of delayed rectifier currents (IK) in hippocampal
neurons and several other neuronal types (Du et al, 2000; Murakoshi & Trimmer,
1999). We therefore studied the effect of AMIGO on neuronal IK in cultured
hippocampal neurons. The expression of AMIGO was inhibited with iRNA and
the IK currents were measured with whole-cell patch-clamp recordings. Following
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inhibition, a clearly reduced amount of AMIGO protein in cell lysates was
confirmed with Western blotting (II: Supplemental Figure S1C). Consistent with
our data from the heterologous expression system in HEK293 cells, the currents
were similar in response to strong membrane depolarization, but inhibition of
AMIGO significantly decreased the current at the threshold of activation (II:
Figure 4). The IK current was activated at higher (more depolarized) membrane
potentials, when AMIGO was inhibited.
4.3 AMIGO KO mice display reduced amount of Kv2.1 protein and
altered electrophysiological properties of neurons (III)
In this study, we have generated mice that lack the Amigo gene (III: Supplementary
Fig. 1). To further understand the physiological role of AMIGO in mouse brain,
we have studied the molecular, electrophysiological, morphological and behavioral
properties of these knockout (KO) mice.
4.3.1 Brain structure of AMIGO KO mice appears normal
AMIGO KO mice develop and breed normally. Their brain morphology was
studied in detail using histological staining approaches. Luxol fast blue/cresyl
violet staining revealed no gross morphological differences between AMIGO KO
and WT brain (III: Figure 1A). Immunostainings for markers of neurons and glial
cells (NeuN, neurofilament M, GFAP, CNPase) were essentially similar in all areas
studied (data not shown).
4.3.2 Decreased amount of Kv2.1 channel in AMIGO KO mouse brain
We compared the amount of Kv2.1 protein in membrane protein samples
prepared from AMIGO KO and WT brains (III:  Figure 1B).  We detected a 45%
reduced  amount  of  Kv2.1  protein  in  AMIGO  KO  brains  as  compared  to  WT.
Similar results were obtained from total brain samples (data not shown).
Kv1.2  antibody  was  used  as  a  control  (III:  Figure  1B).  Kv1.2  is  another
widely expressed Kv channel α-subunit in brain, but the localization of Kv1.2 is
predominantly axonal. The amount of Kv1.2 was unaltered in AMIGO KO mice.
The reduced amount of Kv2.1 was also visible in immunohistochemical
stainings, where the intensity of Kv2.1 immunostaining was clearly lower in
AMIGO KO brain compared to WT (III: Figure 1C).
4.3.3 Localization of Kv2.1 is not altered in the AMIGO KO mouse brain
A number of studies have focused on defining the determinants of the distinct
subcellular distribution of Kv2.1 (Lim et al, 2000; Mohapatra & Trimmer, 2006;
Scannevin et al, 1996). The striking colocalization of AMIGO and Kv2.1
prompted us to consider the possible role of AMIGO in Kv2.1 localization. We
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therefore examined whether the localization of Kv2.1 was altered in AMIGO KO
brain (III: Figure 1C). Although the intensity of Kv2.1 immunohistochemical
staining was clearly weaker in KO brain, the localization of Kv2.1 protein was
unaltered. Kv2.1 remained localized to the soma and proximal part of neurites, and
the staining was clustered in nature.
4.3.4 Voltage-dependent activation of neuronal IK is altered in AMIGO KO mice
Since Kv2.1 is an essential component of the IK current in hippocampal neurons
(Du et al, 2000; Murakoshi & Trimmer, 1999), and the inhibition of AMIGO alters
the voltage-dependent activation of the IK current in cultured hippocampal
neurons (II), we compared the neuronal IK currents in hippocampal slices from
WT and AMIGO KO mice (III: Figure 1D and E). In agreement with our result in
cultured  neurons,  we  found  a  decreased  current  density  in  the  KO  mice  at  the
threshold of activation. The IK current was activated at higher (more depolarized)
membrane potentials in AMIGO KO mice.
4.4 AMIGO KO mice display several schizophrenia-related features
(III)
The  behavioral  phenotype  of  the  AMIGO  KO  mice  was  studied  in  detail  (III:
Table 1). AMIGO KO mice performed normally in a number of behavioral tasks.
However, the KO mice displayed many schizophrenia-related behavioral
abnormalities. Modeling psychiatric disorders in animals is obviously challenging.
However, several characteristics of schizophrenia have correlates in mice such as:
abnormal social behavior, impaired working memory, and defective prepulse
inhibition (PPI) (Lipska & Weinberger, 2000; Powell & Miyakawa, 2006).
Psychotic symptoms are traditionally modeled in mice by studying dopamine-
related behavior such as locomotor activity (Lipska & Weinberger, 2000; Pratt et
al, 2012).
4.4.1 AMIGO KO mice display increased locomotor activity
AMIGO KO mice displayed increased locomotor activity. In an open field, the
KO mice traveled significantly more than the WT littermates (III: Table 1, Figure
2A and B). The increased locomotor activity of AMIGO KO mice was also
evident in the elevated plus maze (III: Table 1). The locomotor activity of the
AMIGO  KO  mice  in  the  open  field  was  reduced  by  the  application  of  the
antipsychotic drug clozapine (1 mg/kg), which could not be observed in the WT
mice (III: Figure 2C and D).
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4.4.2 AMIGO KO mice display sensitivity to psychotomimetic drug
We then tested the effects of the psychotomimetic drug MK-801 in the AMIGO
KO and WT mice  (III:  Figure  2E and  F).  MK-801  is  a  non-competitive  NMDA
receptor antagonist that produces psychosis in humans. Non-competitive NMDA
antagonists are used to model several aspects of schizophrenia in mice and have
been shown to exacerbate symptoms in schizophrenic patients (Lipska &
Weinberger, 2000). The AMIGO KO mice were more sensitive to the locomotor-
activating effect of MK-801 than WT mice. In the WT animals, a low dose of MK-
801  (0.2  mg/kg)  slightly  increased  the  distance  travelled,  but  the  effect  was  not
significantly different from saline. In the KO animals, the same dose significantly
increased the distance travelled.
4.4.3 AMIGO KO mice display reduced prepulse inhibition
The acoustic-startle response was measured in the AMIGO WT and KO mice.
The AMIGO KO mice displayed reduced levels of acoustic startle (III:Table I).
After baseline acoustic startle was established, we measured sensorimotor gating
ability in the form of prepulse inhibition (PPI). PPI is a widely-used
endophenotype of schizophrenia (Turetsky et al, 2007). Several studies have
demonstrated impaired PPI in schizophrenic patients (Gottesman & Gould, 2003;
Keshavan et al, 2008). AMIGO KO mice demonstrated a reduced PPI compared
to WT littermates, which was seen in all prepulse intensities studied (III: Figure
2G).
Antipsychotic drugs improve the impaired PPI in schizophrenic patients and
in animal models of schizophrenia (Kumari & Sharma, 2002). We found that the
antipsychotic drug haloperidol (1 mg/kg) improved the reduced PPI in the
AMIGO KO animals (III: Fig. 1H).
4.4.4 AMIGO KO mice display altered social behavior
When studying social behavior with the resident-intruder test, there was no
significant difference between AMIGO KO and WT mice regarding time that the
animals spent in social or nonsocial activity (III: Table 1). However, this test can
be affected by increased activity of the AMIGO KO mice. Social dominance,
measured using the tube test (III: Table 1), demonstrated that AMIGO KO mice
were significantly more submissive than WT. The WT mice won in 73% of trials
whereas the KO mice won only in 25%.
4.4.5 AMIGO KO mice have impaired cognitive function
We also detected a specific cognitive deficit in the AMIGO  KO  mice.  At  the
outset, no difference from the WT littermates was seen in Morris water maze (data
not shown). Further testing in the IntelliCage platform, which enables automated
monitoring of spontaneous and learning behavior in a home cage-like
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environment, also demonstrated no difference in many of the behavioral
parameters, including group learning and relearning in corner preference task.
AMIGO KO mice did, however, demonstrate a significantly impaired
performance in the IntelliCage patrolling task (III: Table 1), where the mouse has
to learn that the “correct” corner is changed in a clockwise manner after every
“correct” visit to that drinking corner. The task is comparable with the eight-arm
radial maze: both of them test behavioral flexibility and working memory (Too et
al, 2013; Weyer et al, 2011).
4.4.6 Other behavioral properties of AMIGO KO mice
Nociception (Hot plate) and motor coordination (Rota-Rod, Beam walking test) of
the  AMIGO  KO  mice  were  normal  (III:  Table  1).  The  circadian  activity  of  the
AMIGO KO mice was not altered (data not shown). AMIGO KO mice displayed
no abnormalities in spontaneous alternation in Y-maze and IntelliCage (III:
Table 1). From the two tests modeling anxiety-related behavior, the light/dark test
suggested  that  the  AMIGO KO mice  are  more  anxious  (III:  Table  1).  However,
the elevated plus maze suggested that the AMIGO KO mice are less anxious (III:
Table 1). The discrepancy between these two tests may be due to the hyperactivity
of the AMIGO KO mice and dependency of the used tests on general locomotor
activity.
4.4.7 Neurotransmitter analysis of AMIGO KO mice
Several transmitter systems are suggested to be altered in schizophrenic brains,
including dopamine, glutamate, GABA, and serotonin (Keshavan et al, 2008). To
determine whether there are alterations in monoamine neurotransmitter and their
metabolite levels in AMIGO KO mice, we performed HPLC analysis of brain
samples from different areas (III: Supplementary Table 1). The serotonin
concentration in prefrontal and temporal cortex of the KO mice was higher than
in WT mice, whereas the 5-HT turnover (5-HIAA/5-HT ratio) was unchanged.
4.5 Association of KV2.1 variant allele with human schizophrenia (III)
We found altered amount and function of Kv2.1 channel and several
schizophrenia-related abnormalities in the AMIGO KO mice. Our results clearly
identified AMIGO1 and KV2.1 (KCNB1) as candidate genes for human
schizophrenia and related psychiatric disorders. We were especially interested in
the KV2.1 (KCNB1) variation substituting the penultimate amino acid, serine 857
with asparagine (Ser857Asn). Two individuals homozygous for Asn857 have been
identified in a study addressing a possible association of the variant allele with an
EEG trait (Mazzanti et al, 1996). Interestingly, one of the Asn857/Asn857
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homozygotes was reported to have schizophrenia and the other had paranoia.
However, the association of the corresponding single nucleotide polymorphism
(SNP) rs34280195 variant with schizophrenia has not been studied before.
We hypothesized that the allele Asn857 of variation rs34280195 would
comprise a rare, high-impact genetic risk factor for schizophrenia. We analyzed
three nonsynonymous SNPs of KV2.1 (KCNB1) in a Finnish schizophrenia family
sample comprising of 3335 individuals (1209 with schizophrenia spectrum
disorder) from families with multiple cases of schizophrenia (III: Table 2).
According to the hypothesis, the minor allele of Rs34280195, corresponding to
Asn857, associated significantly with schizophrenia and schizophrenia-spectrum
disorders (p = 0.0019 and p = 0.0087, respectively; Bonferroni-corrected p-values
0.01 and 0.05). When we studied the association further we found that the
association was strongest in a subpopulation of our study (p = 1.2 x 10-5 and p =
2.2 x 10-5, for schizophrenia and schizophrenia spectrum disorders, respectively),
which includes families from an internal isolate (IS) with high prevalence of
schizophrenia and a very limited number of founder chromosomes (Hovatta et al,
1997). In the families that were not from the internal isolate, but from all around
Finland (AF families) there was a tendency for association with schizophrenia-
spectrum disorders (p = 0.035, not corrected for multiple testing). No significant
association was evident for rs34467662 and rs112735799 with schizophrenia or
schizophrenia-spectrum disorders in either set of families.
The Ser857Asn variation (rs34280195) was enriched in the IS families. The
allele frequency in the IS families was 0.078. The allele frequency in families with
schizophrenia that were not from the isolate was 0.034. In 1000 Genomes
database, the allele frequency for this variation in Finns is 0.012 (N=93) and in all
reported populations 0.005 (N=1089). Thus, the coding sequence variant
rs34280195 associated highly significantly with schizophrenia and schizophrenia-
spectrum disorders in families from an internal isolate of Finland, and the disease-
associated allele was particularly enriched in these families.
Discussion
44
5. DISCUSSION
5.1 Localization of AMIGO
Several different localizations have been described for AMIGO protein in adult
rodent brains by us and by others with immunohistochemistry using different
antibodies (Chen et al, 2012; Kuja-Panula et al, 2003; Peltola et al, 2011). However,
only the antibody used in publication II in this study has been validated with
AMIGO  KO  mouse  tissue.  With  this  antibody  we  have  defined  the  wide
distribution of AMIGO in cerebral neurons and the localization of AMIGO in
clusters  in  soma  and  proximal  part  of  dendrites.  AMIGO  is  also  shown  to
colocalize with Kv2.1. More recently, the localization of AMIGO to clusters with
Kv2.1 has been replicated with a different antibody, by an independent group, in a
study addressing the coupling of Kv2.1 channels and ryanodine receptors
(Mandikian et al, 2014). The specificity of a monoclonal AMIGO antibody
(Neuromab clone L86A/37) used by Mandikian et al. has also been validated with
AMIGO KO mouse tissue. In conclusion, despite the discrepancy in published
data  about  AMIGO  localization,  we  are  confident  that  AMIGO  localizes  to
clusters at neuronal perisomatic plasma membrane together with Kv2.1. This
localization has been defined with two different antibodies, which are both
validated with AMIGO KO mouse tissue.
5.2 AMIGO as a component of Kv2.1 potassium channel complex
We have identified AMIGO as an integral component of Kv2.1 channel complex
in mouse brain. The association and extensive colozalization of AMIGO and
Kv2.1 in mouse brain and in cultured cells has been demonstrated in this work.
We  have  shown  that  AMIGO  modifies  the  activation  of  Kv2.1  and  neuronal  IK
current. In AMIGO KO mice, the amount of Kv2.1 protein is clearly reduced.
These findings define AMIGO as function-modulating auxiliary subunit of Kv2.1
and thus provides novel insights into regulation of neuronal excitability.
One of the most striking findings of this study was the colocalization of
AMIGO and Kv2.1 proteins: an impressive colocalization was demonstrated in
both mouse brain and cultured hippocampal neurons. In mouse brain, AMIGO
and Kv2.1 colocalized in all anatomical areas examined and the overall distribution
of these two proteins were highly similar. In addition, heterologous expression of
both proteins in HEK293 cells resulted in corresponding colocalization.
Colocalization has rarely been demonstrated as extensively for any other potassium
channel α subunit and its auxiliary subunit. This might partly reflect the
unavailability of antibodies working efficiently in immunohistochemistry. Similarly,
this might partly reflect the ability of auxiliary subunits to associate with several
different α-subunits and the cell type specific regulation of ion channel properties
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by differential combination of α- and auxiliary subunits. Importantly, our
observation that Kv2.1 is in complex with AMIGO implies that the full
understanding of the properties and function of Kv2.1 channel in brain requires
experimental systems where AMIGO is present. Moreover, the wide presence of
AMIGO and Kv2.1 in cerebral neurons indicates that the channel complex
contributes to fundamental properties of neurons.
Two other  auxiliary  proteins  (KChAP and  MiRP2)  have  been  suggested  to
interact with Kv2.1 based on in vitro binding assay or on immunoprecipitation
from rat brain (McCrossan et al, 2003; Wible et al, 1998). Based on in vitro findings,
KCNE5 is also suggested to modulate Kv2.1 (David et al, 2015). Currently, it is
unclear how broadly these proteins associate with the Kv2.1 channel complex in
brain, since the colocalization of native proteins has not been demonstrated.
Auxiliary subunits of ion channels may have several roles in a channel
complex. They are shown to affect the subunit assembly, trafficking, protein
stability, conduction properties, localization, and pharmacological properties of the
channel (Li et al, 2006; Pongs & Schwarz, 2010). In this study, AMIGO is shown
to affect the voltage-dependent activation of Kv2.1, enabling Kv2.1 activation at
lower membrane potentials. Convergent evidence is obtained from three
experimental systems. In HEK293 cells, Kv2.1 current is activated at lower
membrane potentials, when AMIGO is present. In cultured hippocampal neurons,
IK current, which is shown to be largely produced by Kv2.1 (Du et al, 2000;
Murakoshi & Trimmer, 1999), is activated at higher membrane potentials when the
expression of AMIGO is inhibited. Also, the IK current is activated at higher
membrane potentials in the acute hippocampal slices of AMIGO KO mice than in
WT mice. AMIGO thus contributes to neuronal excitability through modulation
of Kv2.1 and IK currents.
Some  of  the  auxiliary  subunits  of  ion  channels  regulate  the  surface
expression of the principal subunit. Nonetheless, Kv2.1 has been reported to lack
intracellular accumulation indicating regulated trafficking, as has been
demonstrated for some other Kv channels. (Manganas & Trimmer, 2000; Shi et al,
1996; Shibata et al, 2003). In all cells examined, Kv2.1 channels are efficiently
trafficked through the endomembrane system and expressed on the cell surface
(Misonou  et  al,  2005b).  In  AMIGO  KO  mice,  we  have  not  detected  any
intracellular accumulation of Kv2.1. This implies that AMIGO might not
contribute to the surface expression of Kv2.1. This is supported by the fact that
AMIGO does not affect the maximal amplitude of Kv2.1 current in HEK293
cells. Nevertheless, levels of Kv2.1 protein were reduced to half in AMIGO KO
mice. Interestingly, AMIGO expression is also reduced in various brain regions in
mice lacking Kv2.1 (Cobb et al, 2013). It seems that both AMIGO and Kv2.1 are
required for the full expression of Kv2.1 channel complex.
Some of the auxiliary subunits of ion channels affect the localization of the
principal subunit. The subcellular localization of Kv2.1 is fascinating. Kv2.1 is
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restricted to the soma and proximal part of neurites, and the localization is highly
clustered (Du et al, 1998; Lim et al, 2000; Scannevin et al, 1996; Trimmer, 1991).
Due to striking colocalization of AMIGO and Kv2.1, we considered the possible
role for AMIGO in regulating the Kv2.1 localization. However, it seems that
AMIGO is not essential for the perisomaly restricted localization of Kv2.1, or for
the formation of Kv2.1 clusters, since this characteristic Kv2.1 localization is
preserved  in  AMIGO  KO  mice.  Kv2.1  is  also  able  to  form  clusters  when
expressed in HEK293 cells (Mohapatra & Trimmer, 2006; O'Connell & Tamkun,
2005), in which no AMIGO is expressed endogenously (II, Supplemental Figure
S1). The nature of Kv2.1 clusters remains largely unknown. Until now, only the
pore forming subunits of Kv2.1 channel complex have been localized to these
plasma-membrane sites in brain (Kihira et al, 2010; Trimmer, 1991). Clustering of
Kv2.1 illustrates that neurons possess specialized membrane domains that are still
poorly understood. Hopefully, identification of AMIGO in these sites will facilitate
the understanding of these membrane domains in neurons.
The extracellular parts of Kv2.1 protein are very small. The presence of
AMIGO brings an additional extracellular component to the Kv2.1 channel
complex. AMIGO is also significantly glycosylated, whereas the extracellular parts
of Kv2.1 are not glycosylated (Chen et al, 2012; Kajander et al, 2011; Shi &
Trimmer, 1999). The extracellular part of AMIGO contains LRR- and Ig-domains
and thus provides a motif for protein interaction and cell adhesion. Cell adhesion
molecules are well known as auxiliary subunits for sodium channels. Beta subunits
of voltage-gated sodium channels are transmembrane proteins with an Ig-domain
and several glycosylation sites (Isom et al, 1992). AMIGO is the first Ig-domain-
containing auxiliary subunit associated with a potassium channel. Beta subunits (β1
and β2) of sodium channels are multifunctional. They serve both as modulators of
channel gating and as cell-adhesion molecules, affecting cell-cell interaction and
binding extracellular matrix and cytoskeletal proteins (Brackenbury et al, 2008).
Kv2.1 clusters at the plasma membrane lie over ER-derived structures called
subsurface  cisterns  (Du  et  al,  1998).  These  membrane  discs  are  rich  in  inositol
triphosphate receptors and ryanodine receptors and are very closely associated
with plasma membrane (Berridge, 1998; Rosenbluth, 1962). Kv2.1 clusters are
shown to reside in extra-synaptic areas and to be faced by astrocytic processes in
pyramidal neurons (Du et al, 1998; Misonou et al, 2008). In motor neurons, Kv2.1
clusters are strongly associated with cholinergic synapses (Muennich & Fyffe,
2004). It is tempting to speculate whether AMIGO contributes to localization of
Kv2.1 in respect to extra- or intracellular structures associated with Kv2.1 clusters,
such as subsurface cisterns or astrocytic processes.
Several stimuli can induce dispersion of Kv2.1 from clusters. Diffusion is
induced in rat brain by kainate-induced seizures or in cultured neurons by
glutamate stimulation (Misonou et al, 2004; Misonou et al, 2006). Similar changes
are induced by hypoxia/ischemia produced by CO2 treatment in rat brain or by a
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chemical ischemia model in cultured neurons (Misonou et al, 2005a). All of these
stimuli are related to excitotoxicity and it is unclear whether the diffusion is
associated only with pathological situations or also with normal physiological
function. Mechanisms of dispersion are described and discussed extensively
elsewhere (Misonou et al, 2004; Misonou et al, 2005a; Misonou et al, 2006;
Misonou et al, 2008; Mohapatra & Trimmer, 2006; Mohapatra et al, 2008;
Mulholland et al, 2008). In this study, we would like to emphasize the observations
that the association and colocalization of AMIGO and Kv2.1 is preserved during
dramatic stimulus-induced changes in Kv2.1 channel localization. These
observations emphasize the role of AMIGO as an integral component of the
Kv2.1 channel complex.
The AMIGO protein family contains two other homologous proteins:
AMIGO2 and AMIGO3. It  is  possible that  these proteins interact  with Kv2.1 or
with a related potassium channel α-subunit, Kv2.2. According to our studies,
AMIGO2 and AMIGO3 are expressed in tissues outside the nervous system more
widely than AMIGO. In the nervous system, the expression of AMIGO2 is
detected in restricted brain areas (Laeremans et al, 2013). It is likely that further
studies, and especially the development of novel antibodies, will clarify the detailed
distribution and function of the other AMIGOs in the future. Similarly, the
possible colocalization and association of AMIGOs with the other Kv2 family
member, Kv2.2, will be an interesting subject for future studies. In contrast to the
ubiquitous expression of Kv2.1, the expression of Kv2.2 in rat brain is relatively
limited and restricted to specific brain areas (Hermanstyne et al, 2010; Kihira et al,
2010).
5.3 AMIGO-Kv2.1 channel complex in schizophrenia-related
phenotypes
AMIGO KO mice display several alterations that are used to model schizophrenia
in rodents. These include increased locomotor activity, sensitivity to the
psychotomimetic drug MK-801, altered social behavior, and impaired PPI and
cognitive function. In addition, the pharmacological response of the AMIGO KO
mice suggests similarity to human disease, since the antipsychotic drugs are able to
relieve the hyperactivity and the impaired PPI. Several transmitter systems are
implicated to be altered in schizophrenic brains, including dopamine, glutamate,
GABA, and serotonin (Keshavan et al, 2008). In this study, increased serotonin
concentrations were detected in the prefrontal and temporal cortex of AMIGO
KO brains.  Functional  alterations  in  these  brain  areas  are  associated  with  human
schizophrenia (Keshavan et al, 2008). It is quite intriguing to find this many
schizophrenia-related abnormalities in a mouse line lacking a single gene. It is
especially noteworthy that behavioral abnormalities relevant to all three major
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symptom clusters of schizophrenia are present in the AMIGO KO mice. Even the
mouse models created by deleting known schizophrenia-associated genes do not
generally recapitulate the breadth of the schizophrenia clinical profile (Carpenter &
Koenig, 2008).
The behavioral disturbances of the AMIGO KO mice are likely to be
mediated through altered function of the Kv2.1 potassium channel. In AMIGO
KO mice, the amount of Kv2.1 protein is clearly decreased and voltage-dependent
activation of neuronal IK,  largely  attributable  to  Kv2.1,  is  altered.  Our  results  are
supported by the recent finding that the Kv2.1 (alias Kcnb1) -deficient mice are
strikingly hyperactive (Speca et al, 2014), clearly resembling the hyperactivity
phenotype of the AMIGO KO mice found in our study. Kv2.1-deficient mice also
exhibit defects in spatial learning. However, the behavioral phenotype of the Kv2.1
deficient mice has not been previously compared to schizophrenia. Furthermore,
occurrence of AMIGO as a part of the Kv2.1 channel complex is conserved
across species and was also recently demonstrated in adult zebrafish brain (Zhao et
al, 2014). Due to our findings on mice, behavioral characteristics and the
expression of Kv2.1 were studied also in zebrafish. Indeed, knockdown of amigo in
zebrafish essentially abolishes the expression of the Kv2.1 protein and leads to
behavioral alterations characterized by hyperactivity and defective escape
responses. Interestingly, the behavioral alterations in the amigo knockdown
morphant can be rescued by injection of kv2.1 mRNA. Knockdown of amigo in
zebrafish also leads to early developmental defects in fiber pathways of the brain.
However, these developmental defects are not rescued by kv2.1 mRNA (Zhao et
al, 2014). Therefore, it seems that behavioral regulation by Amigo in zebrafish
critically depends on Kv2.1, whereas the role of Amigo in fiber-pathway
development does not depend on Kv2.1.
After our study was completed, but not yet published, KV2.1 (KCNB1)
emerged as a candidate gene for schizophrenia also in a large international GWAS
meta-analysis, as common variants located at chromosome 20q13.13 in the vicinity
of KCNB1 and PTGIS genes were found to associate modestly with schizophrenia
(OR = 1.07) (Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014). Only about one third of the heritability of schizophrenia has
been estimated to be captured by the common variations included in genotyping
platforms used in the large-scale genome-wide analyses, and relatively rare, high-
impact variations have been suggested to contribute to the missing heritability of
schizophrenia (Ripke et al, 2013; Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). Variants are typically distributed in varying
frequencies among different populations. The unique population history,
distinctive pattern of rare functional variants (Lim et al, 2014), and presence of
regional isolates with high risk for schizophrenia (Perälä et al, 2008), makes Finns
an ideal population to target these rare disease-causing variants for schizophrenia,
as was recently demonstrated for population from Northern Finland (Stoll et al,
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2013). We have now been able to detect an association of a rare coding variant of
KV2.1 (KCNB1) with schizophrenia and schizophrenia spectrum disorders. We
have thus established the role of KV2.1 (KCNB1) as a schizophrenia susceptibility
gene.
Interestingly, in addition to identifying KV2.1 (KCNB1) as a candidate gene
for schizophrenia, the largest GWAS study of schizophrenia also implicated locus
containing KCNV1 gene (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). KCNV1 encodes “silent” Kv8.1 potassium channel
subunit, which fails to produce electrically functional channels alone, but is able to
interact with Kv2.1 and modify the Kv2.1 channel activity (Chiara et al, 1999;
Ottschytsch et al, 2002; Salinas et al, 1997a).
Kv2.1 is strongly regulated by NMDA receptors, calcium signaling, and
calcineurin (PP2B). All of these mechanisms are also connected to schizophrenia.
(Fromer et al, 2014; Gerber et al, 2003; Kirov et al, 2012; Schizophrenia Working
Group of the Psychiatric Genomics Consortium, 2014).
Kv2.1 regulates excitability during periods of high-frequency firing and is
suggested  to  function  as  a  component  of  homeostatic  plasticity  (Du  et  al,  2000;
Surmeier & Foehring, 2004). Altered Kv2.1 channel complex is thus expected to
lead to a situation where neurons are more prone to high-frequency firing without
proper homeostatic control. Since Kv2.1 channels are widely expressed in different
brain regions, and present in pyramidal neurons as well as inhibitory interneurons,
altered Kv2.1 activity could have complex effects on overall brain function.
Organized neuronal firing is crucial for brain function. Neural oscillations
are linked to several important brain functions disturbed in schizophrenia, such as
consciousness, attention, memory, and sensory processing (Uhlhaas & Singer,
2010). Since potassium channels play a central role in neuronal synchronization,
the schizophrenia-like behavior resulting from AMIGO/Kv2.1 disruption could at
least partially be accounted for by disturbed synchrony and cortical oscillations
associated with schizophrenia (Uhlhaas & Singer, 2010).
The phosphorylation, localization, and activity of Kv2.1 are shown to be
coupled (Misonou et al, 2004; Misonou et al, 2005b). In this respect, it is relevant
that the Ser857Asn variation replaces a phosphorylation target serine with
asparagine. Disrupted Kv2.1 phosphorylation could affect the localization and
activity of the channel and thus alter the neuronal excitability.
Hypoxia-ischemia-related fetal and neonatal complications are associated
with increased risk of schizophrenia (Cannon et al, 2000; Zornberg et al, 2000).
Predisposing genetic factors might interact with hypoxia in increasing the risk of
schizophrenia. Interestingly, the phosphorylation, localization and activity of
Kv2.1 are strongly regulated by hypoxia/ischemia (Misonou et al, 2004; Misonou
et al, 2005a; Misonou et al, 2008). Kv2.1 is suggested to function as a mechanism
to suppress pathological hyperexcitability of central neurons during ischemic
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conditions (Misonou et al, 2005a). Disrupted Kv2.1 phosphorylation could affect
the channel responsiveness to hypoxia and thus predispose to ischemic injury.
Our convergent findings in humans and mice suggest a role for the
AMIGO-Kv2.1 potassium channel complex in pathophysiology of schizophrenia.
Including our study and recent findings on other channels, there is now emerging
evidence that voltage-dependent potassium channels and their interaction partners
may contribute to the pathophysiology of schizophrenia and related psychiatric
disorders. In addition to GWAS findings mentioned above, Kv11.1 gene
(KCNH2) is linked to an increased risk of schizophrenia and shown to affect
cortical physiology, cognition, and antipsychotic treatment response (Apud et al,
2012; Huffaker et al, 2009). The gene encoding Caspr2 (CNTNAP2), an adhesion
protein interacting with Kv1 potassium channels, has been associated with
schizophrenia and epilepsy (Friedman et al, 2007). Kv7.2 gene (KCNQ2) has been
associated with bipolar disorder (Borsotto et al, 2006). Additionally, it has been
shown that the amount of Kv3.1 channels is reduced in patients with untreated
schizophrenia (Yanagi et al, 2013). The finding is interesting since AMIGO KO
mice exhibit a reduced amount of Kv2.1.
Some studies have observed that potassium channel activators have
antipsychotic effects (Akhondzadeh et al, 2002; Sotty et al, 2009; Vukadinovic &
Rosenzweig,  2012).  It  is  also suggested that  the current antipsychotic drugs could
mediate part of their therapeutic actions by affecting potassium channels since
variation in Kv11.1 gene (KCNH2) modulates antipsychotic treatment response in
patients with schizophrenia (Apud et al, 2012). Additionally, it has been shown
that  the  amount  of  Kv3.1  channels  is  reduced  in  patients  with  untreated
schizophrenia and normalized with antipsychotic drugs (Yanagi et al, 2013). Our
findings  emphasize  the  role  of  potassium  channels  as  attractive  targets  for
treatment development for schizophrenia, and identify two novel drug target
candidates; AMIGO and Kv2.1. Based on the murine studies presented here,
agents modifying the function of AMIGO-Kv2.1 channel complex might have
broader effects on schizophrenia symptoms than traditional antipsychotics. From
these two molecules, AMIGO has a significantly larger extracellular part and is
therefore more accessible as a drug target. Additionally, the crystal structure of the
extracellular part of AMIGO is solved (Kajander et al, 2011), facilitating structure-
based drug design. From the viewpoint of treatment development, it is good to
bear in mind that Kv2.1 channels play role in several physiological processes
outside the nervous system. Kv2.1 is shown to function in cardiac ventricular
repolarization (Xu et al, 1999), insulin secretion by pancreatic β-cells (MacDonald
et al, 2002), and hypoxic pulmonary vasoconstriction (Archer et al, 1998; Patel et
al, 1997). The detailed expression profile of AMIGO outside the nervous system
remains to be determined. However, based on our study the expression of
AMIGO is more restricted to the nervous system. AMIGO therefore appears as a
potentially more specific target for drug development.
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6. CONCLUSIONS
- A novel neuronal transmembrane protein, AMIGO, has been identified.
AMIGO defines a novel LRR protein family together with AMIGO2 and
AMIGO3.
- AMIGO is predominantly expressed in the central nervous system and
widely present in cerebral neurons. At the subcellular level, AMIGO
localizes to distinct clusters at the neuronal plasma membrane of cell soma
and proximal part of neurites.
- AMIGO is an integral component of Kv2.1 potassium channel complex in
brain. AMIGO fine-tunes the electrophysiological properties of the Kv2.1
channel.
- The phenotypic characteristics found in the AMIGO knockout mice
demonstrate the involvement of AMIGO-Kv2.1 channel complex in
schizophrenia-related behavioral disturbances in mice.
- KV2.1 (KCNB1) is a susceptibility gene for schizophrenia and
schizophrenia spectrum disorders in humans.
- Our convergent findings in humans and mice suggest a role for AMIGO-
Kv2.1 potassium channel complex in the pathophysiology of
schizophrenia. Our results define AMIGO and Kv2.1 as potential new
drug targets for schizophrenia.
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